program farmasi / pharmacy programme

72

Upload: lamdung

Post on 31-Dec-2016

263 views

Category:

Documents


4 download

TRANSCRIPT

Page 1: program farmasi / pharmacy programme
Page 2: program farmasi / pharmacy programme

PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

VISI, MISI DAN OBJEKTIF VISION, MISSION AND OBJECTIVE

CARTA ORGANISASIORGANIZATIONAL CHART

PENGURUSAN TERTINGGI TOP MANAGEMENT

PENGENALAN INTRODUCTION

SUMBER MANUSIA DAN MODAL INSAN ORGANIZATION AND HUMAN RESOURCE DEVELOPMENT

BAHAGIAN PERKHIDMATAN FARMASI PHARMACEUTICAL SERVICES DIVISION

BIRO PENGAWALAN FARMASEUTIKAL KEBANGSAAN NATIONAL PHARMACEUTICAL CONTROL BUREAU

HALATUJU WAY FORWARD

KESIMPULAN SUMMARY

JAWATANKUASA EDITORIAL EDITORIAL COMMITTEE

LAMPIRAN ANNEXURE

23458

143644

4847

50

KANDUNGAN CONTENTS

Page 3: program farmasi / pharmacy programme

2 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

VisiMenerajui pengurusan berkualiti ke atas ubat-ubatan melalui tenaga kerja yang berdaya saing, sains dan teknologi bersesuaian dan perkongsian dengan semua pihak

yang berkepentingan.

MisiMemastikan ubat-ubatan berkualiti

untuk negara

ObjektifMemastikan semua keluaran farmaseutikal dan produk penjagaan kesihatan yang berada di pasaran adalah berkualiti, selamat, berkesan dan dikawal mengikut undang-undang yang berkaitan serta

digunakan secara rasional.

VisionLeading in quality management of medicine through a competent pharmacy workforce and appropriate science and technology development in partnership with stakeholders

MissionEnsuring quality medicines for the nation

ObjectivesEnsuring all pharmaceutical and health products in the market are of quality, safe and efficacious to relevant legislations and used rationally

Page 4: program farmasi / pharmacy programme

3PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

DASA

R  &  PENG

URUS

AN  

FARM

ASI  

PHAR

MAC

Y  POL

ICY  &

 MAN

AGEM

ENT  

AMALAN

 DAN

 PERK

EMBA

NGAN

 FARM

ASI  

PHAR

MAC

Y  PRA

CTICE  A

ND  

DEVE

LOPM

ENT  

PENG

UATKUA

SAAN

 FA

RMAS

I  PH

ARMAC

Y  ENF

ORCEMEN

T  

BIRO

 PENG

AWALAN

 FA

RMAS

EUTIK

AL  

KEBA

NGSA

AN  

NATIO

NAL  

PHAR

MAC

EUTIC

AL  CO

NTRO

L  BU

REAU

   

BAHA

GIAN

 PERK

HIDM

ATAN

 FA

RMAS

I  NEG

ERI  

STAT

E  PHA

RMAC

EUTIC

AL  

SERV

ICES  DIVISION

 

HOSPITA

L  KUA

LA  LU

MPU

R  KU

ALA  LU

MPU

R  HO

SPITA

L  

KERJAY

A  &  MOD

AL  IN

SAN  

CARE

ER  &  HUM

AN  CA

PITA

L  FA

RMAS

I  KLIN

IKAL  &  TE

KNIKAL  

CLINICAL  &  TE

CHNICA

L  PHA

RMAC

Y  OP

ERAS

I  &  SIAS

ATAN

 OP

ERAT

ION  &  INVISTIGAT

ION  

DASA

R  UB

AT  NAS

IONA

L  NA

TIONA

L  MED

ICINES  PO

LICY  

FORM

ULAR

I  &  FA

RMAK

OEKO

NOMIK  

FORM

ULAR

Y  &  PH

ARMAC

OECO

NOMICS  

PELESENA

N  LIC

ENSIN

G  

DASA

R  FA

RMAS

I  PH

ARMAC

Y  POL

ICY  

LOGISTIK  FA

RMAS

EUTIK

AL  

PHAR

MAC

EUTIC

AL  LO

GISTICS  

PERU

NDAN

GAN  

LEGISLAT

ION  

PENG

URUS

AN  M

AKLU

MAT

 FARM

ASI  

PHAR

MAC

Y  INF

ORMAT

ION  MAN

AGEM

ENT  

SYSTEM

 PERK

EMBA

NGAN

 FARM

ASI  

PHAR

MAC

Y  DEV

ELOP

MEN

T  PENG

IKLANA

N  &  INOV

ASI  

ADVE

RTISE

MEN

T  &  IN

NOVA

TION  

PENT

ADBIRA

N  &  KEWAN

GAN  

ADMINIST

RATIO

N  &  FIN

ANCE  

PENG

GUNA

AN  UBA

T  BER

KUALITI  

QUALITY

 USE  OF  M

EDICINES  

PENC

EGAH

AN  &  KE

SEDA

RAN  

PENG

GUNA

 PR

EVEN

TION  &  CO

NSUM

ER  

PROT

ECTIO

N  

LEMBA

GA  FA

RMAS

I  PH

ARMAC

Y  BOA

RD  

HARG

A  UB

AT  

MED

ICINE  P

RICE  

PENG

ARAH

 KANA

N  PERK

HIDM

ATAN

 FARM

ASI  

SENIOR

 DIRECTO

R  OF

 PHAR

MAC

EUTIC

AL  SE

RVICES  DIVISION

 

PUSA

T  KAW

ALAN

 KUALITI  

CENT

RE  FO

R  QU

ALITY

 CONT

ROL  

PUSA

T  PEN

DAFTAR

AN  PR

ODUK

 CENT

RE  FO

R  PR

ODUC

T  REG

ISTRA

TION  

PUSA

T  PAS

CA  PE

NDAF

TRAN

 PROD

UK  

CENT

RE  FO

R  PO

ST-­‐REG

ISTRA

TION  OF

 PR

ODUC

T  

PUSA

T  KOM

PLIANS

 &  PE

RLESEN

AN  

CENT

RE  FO

R  CO

MPLIANC

E  &  

LICEN

CING

 

PUSA

T  PEM

BANG

UNAN

 ORG

ANISA

SI  CENT

RE  FO

R  OR

GANISA

TIONA

L  DE

VELO

PMEN

T  

PUST  PE

NTAD

BIRA

N  CENT

RE  FO

R  AD

MINIST

RATIO

N  

TIMBA

LAN  PE

NGAR

AH    

DEPU

TY  DIRECTO

R    

PENG

ARAH

 DIRE

CTOR

   PE

NGAR

AH    

DIRE

CTOR

 PE

NGAR

AH  

DIRE

CTOR

 TIMBA

LAN  PE

NGAR

AH  

KESIH

ATAN

 NEG

ERI  

(FAR

MAS

I)  STAT

E  HEA

LTH  DE

PUTY

 DIRE

CTOR

 (PHA

RMAC

Y)  

KETU

A  PE

GAWAI  FA

RMAS

I  CH

IEF  PH

ARMAC

IST  

KETU

A  PR

OGRA

M  FA

RMAS

I  HE

AD  OF  P

HARM

ACY  P

ROGR

AM  

CA

RTA

ORG

AN

ISA

SI O

RGA

NIZ

ATIO

NA

L C

HART

Page 5: program farmasi / pharmacy programme

4 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

PENGURUSAN TERTINGGI TOP MANAGEMENT

YBHG. DATO’ EISAH BINTI A. RAHMANPENGARAH KANAN PERKHIDMATAN FARMASI

SENIOR DIRECTOR OF PHARMACEUTICAL SERVICES

TUAN HJ. MOHD HATTA BIN AHMADPENGARAH

PENGUATKUASAAN FARMASIDIRECTOR OF PHARMACY ENFORCEMENT

DR. SALMAH BINTI BAHRIPENGARAH

AMALAN DAN PERKEMBANGAN FARMASIDIRECTOR OF PHARMACY PRACTICE AND

DEVELOPMENT

ENCIK TAN ANN LINGPENGARAH

BIRO PENGAWALAN FARMASEUTIKAL KEBANGSAAN (BPFK)

DIRECTOR OF NATIONAL PHARMACEUTICALCONTROL BUREAU (NPCB)

DR. NOUR HANAH BINTI OTHMANTIMBALAN PENGARAH

DASAR & PENGURUSAN FARMASIDEPUTY DIRECTOR OF PHARMACY

POLICY & MANAGEMENT

Page 6: program farmasi / pharmacy programme

5PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

PENGENALAN INTRODUCTION

Program Farmasi, Kementerian Kesihatan Malaysia (KKM) merupakan agensi utama yang bertanggungjawab memastikan ubat-ubatan adalah berkualiti untuk negara. Program ini terdiri daripada empat Bahagian utama iaitu Dasar dan Pengurusan Farmasi, Amalan dan Perkembangan Farmasi, Penguatkuasaan Farmasi dan Biro Pengawalan Farmaseutikal Kebangsaan. Keempat-empat aktiviti tersebut memainkan peranan penting dalam aspek-aspek yang berbeza tetapi mempunyai satu matlamat yang sama iaitu untuk memberikan perkhidmatan farmasi yang terbaik kepada orang ramai.

The Pharmacy Programme of the Ministry of Health (MOH) is the lead agency in ensuring quality medicines for the nation. The Programme is headed by a Senior Director who is responsible of four main activities namely Policy and Pharmacy Management, Pharmacy Practice and Development, Pharmacy Enforcement and National Pharmaceutical Control Bureau (NPCB). These four main activities play important roles in different aspects and approaches but with the same objective, that is giving the best professional pharmacy service to the public.

Page 7: program farmasi / pharmacy programme
Page 8: program farmasi / pharmacy programme

SUMBER MANUSIA DAN MODAL INSAN

ORGANIZATIONAL AND HUMAN RESOURCE DEVELOPMENT

Page 9: program farmasi / pharmacy programme

8 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

SUMBER MANUSIA DAN MODAL INSANORGANIZATIONAL AND HUMAN RESOURCE DEVELOPMENT

5 | L a p o r a n T a h u n a n 2 0 1 2

SUMBER MANUSIA DAN MODAL INSAN

ORGANIZATIONAL AND HUMAN RESOURCE DEVELOPMENT

Jadual 1: Bilangan Pendaftaran oleh Lembaga Farmasi (2006-2012)

Table 1: Number of Registrations by Pharmacy Board of Malaysia (2006-2012)

Perkara Description Tahun Year

2006 2007 2008 2009 2010 2011 2012 Bilangan Ahli Farmasi Baru Berdaftar Number of Newly Registered Pharmacists

437

534

617 705 739 934 918

Bilangan Ahli Farmasi Provisional Berdaftar Number of Provisionally Registered Pharmacists

529 614 722 813 925 922 1,208

Bilangan Pertubuhan Perbadanan Berdaftar Number of Registered Body Corporates

107 98 43 48 48 44 57

Bilangan Sijil Pengekalan Tahunan/Sijil Tahunan Ahli Farmasi Number of Pharmacist Annual Retention Certificates

4,292 4,422 5,924 5,507 8,852 8,746 8,968

Bilangan Sijil Pengekalan /Sijil Tahunan Pertubuhan Perbadanan Number of Body Corporate Annual Retention Certificates

270 414 371 445 663 794 548

Page 10: program farmasi / pharmacy programme

9PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

6 | L a p o r a n T a h u n a n 2 0 1 2

Bilangan perjawatan bagi Program Farmasi di BPF, KKM adalah seperti di Jadual 2.

The number of posts for pharmacy personnel at PSD, MOH is shown in table 2.

Jadual 2: Bilangan Jawatan Anggota Farmasi di BPF, KKM

Table 2: Number of Posts of Pharmacy Personnel

7 | L a p o r a n T a h u n a n 2 0 1 2

Jadual 3: Bilangan Jawatan Anggota Farmasi di BPFK

Table 3: Number of Posts at National Pharmaceutical Control Bureau (NPCB)

Jadual 4: Bilangan Jawatan Anggota Farmasi di KKM

Table 4: Number of Posts at MOH

Bilangan perjawatan bagi Program Farmasi di BPF, KKM adalah seperti di Jadual 2.The number of posts for pharmacy personnel at PSD, MOH is shown in table 2.

Page 11: program farmasi / pharmacy programme

10 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

7 | L a p o r a n T a h u n a n 2 0 1 2

Jadual 3: Bilangan Jawatan Anggota Farmasi di BPFK

Table 3: Number of Posts at National Pharmaceutical Control Bureau (NPCB)

Jadual 4: Bilangan Jawatan Anggota Farmasi di KKM

Table 4: Number of Posts at MOH

Page 12: program farmasi / pharmacy programme

11PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

8 | L a p o r a n T a h u n a n 2 0 1 2

Latihan Training

Bilangan latihan yang dikendalikan dalam tahun 2012.

Number of training conducted in the year 2012.

Jadual 5: Pelaksanaan Kursus Dalam Negara BPF, KKM

Table 5: Training Conducted Locally by PSD, MOH

Jadual 6: Bilangan Latihan Dalam Negara BPFK

Table 6: Training Conducted Locally by NPCB

Jenis latihan Types of Training

Bilangan latihan No. of Training

Bilangan peserta latihan No. of Attendance

Kursus | Courses 18 501 Seminar | Seminars 5 229 Sesi CME | CME Session 28 1,431 Sesi Latihan | Training Session 86 1,246 Bengkel | Workshop 11 276 JUMLAH TOTAL 148 3,683

Jadual 7: Pelaksanaan Kursus Luar Negara BPF dan BPFK

Table 7: Training Conducted Overseas by PSD and NPCB

Tahun Year

Bil. Kursus Dijalankan No. of Courses

Conducted

Bil. Pegawai Menghadiri No. of Attendance

2012 (BPF | PSD) 6 7

2012 (BPFK | NPCB) 51 115

Tahun Year

Peringkat Ibu Pejabat HQ

Peringkat Institusi & Negeri Institution & States

Bil. Kursus Dijalankan

No. of Courses Conducted

Bil. Pegawai Menghadiri

No. of Attendance

Bil. Kursus Dijalankan

No. of Courses Conducted

Bil. Pegawai Menghadiri

No. of Attendance

2012 69 2,706 285 12,013

Latihan Training

Bilangan latihan yang dikendalikan dalam tahun 2012.Number of training conducted in the year 2012.

Page 13: program farmasi / pharmacy programme
Page 14: program farmasi / pharmacy programme

BAHAGIAN PERKHIDMATAN FARMASI

PHARMACEUTICAL SERVICES DIVISION

Page 15: program farmasi / pharmacy programme

14 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

PENCAPAIAN TAHUN 2012 ACHIEVEMENTS IN YEAR 2012

BAHAGIAN PERKHIDMATAN FARMASI PHARMACEUTICAL SERVICES DIVISION

1. Perbelanjaan Produk Farmaseutikal (Ubat dan Bukan Ubat) KKM

MOH Pharmaceutical Products (Medicines and Non Drug) Expenditure

Pada tahun 2012, nilai perolehan ubat-ubatan di semua hospital dan klinik kesihatan KKM ialah sebanyak RM1,983 juta. Nilai perbelanjaan bagi ubat – ubatan tersebut meningkat sebanyak 12.2% berbanding tahun 2011. Nilai perolehan bagi bukan ubat pula sebanyak RM683.6 juta. Nilai stok penutup bagi ubat dan bukan ubat pada bulan Disember 2012 adalah RM296.1 juta, iaitu kira-kira 1.3 bulan pegangan stok.

The total cost of medicines procured in 2012 for all MOH hospitals and health clinics was RM1, 983 million. This shows an increase of 12.2% in medicines expenditure compared to 2011. The total cost of non-drug procured was RM683.6 million. The amount of closing stock for medicines and non-drug in December 2012 was RM296.1 million, which is about 1.3 months of stock holding.

9 | L a p o r a n T a h u n a n 2 0 1 2

PENCAPAIAN TAHUN 2012

ACHIEVEMENTS IN YEAR 2012

BAHAGIAN PERKHIDMATAN FARMASI

PHARMACEUTICAL SERVICES DIVISION

1. Perbelanjaan Produk Farmaseutikal (Ubat dan Bukan Ubat) KKM

MOH Pharmaceutical Products (Medicines and Non Drug) Expenditure

Pada tahun 2012, nilai perolehan ubat-ubatan di semua hospital dan klinik kesihatan KKM ialah

sebanyak RM1,983 juta. Nilai perbelanjaan bagi ubat – ubatan tersebut meningkat sebanyak 12.2%

berbanding tahun 2011. Nilai perolehan bagi bukan ubat pula sebanyak RM683.6 juta. Nilai stok

penutup bagi ubat dan bukan ubat pada bulan Disember 2012 adalah RM296.1 juta, iaitu kira-kira 1.3

bulan pegangan stok.

The total cost of medicines procured in 2012 for all MOH hospitals and health clinics was RM1, 983

million. This shows an increase of 12.2% in medicines expenditure compared to 2011. The total cost

of non-drug procured was RM683.6 million. The amount of closing stock for medicines and non-drug in

December 2012 was RM296.1 million, which is about 1.3 months of stock holding.

Jadual 8: Perbelanjaan Produk Farmaseutikal KKM (2010-2012)

Table 8: MOH Pharmaceutical Products Expenditure (2010-2012)

Tahun Year

Jumlah Perbelanjaan

(RM Juta) Total Expenditure

(RM Million)

% Peningkatan Berbanding Tahun

Sebelumnya % Increment Over the Previous Year

2010 1605.54 14.48

2011 1767.61 10.09

2012 1983.51 12.21

10 | L a p o r a n T a h u n a n 2 0 1 2

Jadual 9: Kaedah Perolehan Tahun 2012

Table 9: Types of Medicines Procurement in 2012

2. Formulari Ubat KKM

MOH Drug Formulary

Rajah 1: Penyenaraian Ubat dalam Formulari Ubat (2001-2012)

Figure 1: Drugs Listed into MOH Drug Formulary (2001-2012)

Pada tahun 2012, 3 ubat telah dikeluarkan daripada formulari manakala 51 ubat baru termasuk

kekuatan atau formulasi baru telah disenaraikan dalam formulari ubat KKM. Ini menjadikan

keseluruhan ubat dalam Formulari Ubat KKM berjumlah 1578 pada akhir tahun 2012 (Rajah 1).

In 2012, 3 drugs have been removed from the formulary while 51 drugs, including new formulations or

strengths, were listed into the formulary. As a result, there were a total of 1578 preparations in the

MOH Drug Formulary at the end of 2012 (Figure 1).

Tahun

Year

APPL

(RM)

KKM Kontrak

MOH Contract

(RM)

Pembelian Terus & Sebutharga

Local Purchase & Quotation

(RM)

2012 810,332,787 (41%) 760,829,333 (38%)

412,355,654 (21%)

Page 16: program farmasi / pharmacy programme

15PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

10 | L a p o r a n T a h u n a n 2 0 1 2

Jadual 9: Kaedah Perolehan Tahun 2012

Table 9: Types of Medicines Procurement in 2012

2. Formulari Ubat KKM

MOH Drug Formulary

Rajah 1: Penyenaraian Ubat dalam Formulari Ubat (2001-2012)

Figure 1: Drugs Listed into MOH Drug Formulary (2001-2012)

Pada tahun 2012, 3 ubat telah dikeluarkan daripada formulari manakala 51 ubat baru termasuk

kekuatan atau formulasi baru telah disenaraikan dalam formulari ubat KKM. Ini menjadikan

keseluruhan ubat dalam Formulari Ubat KKM berjumlah 1578 pada akhir tahun 2012 (Rajah 1).

In 2012, 3 drugs have been removed from the formulary while 51 drugs, including new formulations or

strengths, were listed into the formulary. As a result, there were a total of 1578 preparations in the

MOH Drug Formulary at the end of 2012 (Figure 1).

Tahun

Year

APPL

(RM)

KKM Kontrak

MOH Contract

(RM)

Pembelian Terus & Sebutharga

Local Purchase & Quotation

(RM)

2012 810,332,787 (41%) 760,829,333 (38%)

412,355,654 (21%)

2. Formulari Ubat KKM MOH Drug Formulary

3. Dasar dan Perundangan Workshops and Legal Framework

Bengkel Kajian Penuh Dasar Ubat Nasional (DUNas)Full Term Review of Malaysia National Medicines Policy Workshop (MNMP)

Bengkel Kajian Penuh Dasar Ubat Nasional (DUNas) telah diadakan pada 15-17 Oktober 2012 di Holiday Villa Hotel & Suites, Subang, Selangor. Objektif bengkel ini diadakan adalah untuk menilai semula pencapaian, kelemahan dan kesesuaian strategi yang telah dilaksanakan sejak tahun 2006 - 2012 serta mencadangkan komponen dan strategi baru bagi 5 tahun akan datang. Bengkel ini melibatkan semua pihak yang berkepentingan memandangkan input dan persetujuan semua pihak adalah penting bagi menggubal dasar yang akan menentukan hala tuju sektor farmaseutikal pada tahun-tahun akan datang. Seramai 150 peserta dari pelbagai badan profesional, persatuan-persatuan pengguna dari industri yang berkaitan, agensi-agensi kerajaan dan kementerian serta universiti telah menghadiri bengkel ini.

Pada tahun 2012, 3 ubat telah dikeluarkan daripada formulari manakala 51 ubat baru termasuk kekuatan atau formulasi baru telah disenaraikan dalam formulari ubat KKM. Ini menjadikan keseluruhan ubat dalam Formulari Ubat KKM berjumlah 1578 pada akhir tahun 2012 (Rajah 1).

In 2012, 3 drugs have been removed from the formulary while 51 drugs, including new formulations or strengths, were listed into the formulary. As a result, there were a total of 1578 preparations in the MOH Drug Formulary at the end of 2012 (Figure 1).

Page 17: program farmasi / pharmacy programme

16 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

Intipati dasar sedia ada yang memberi penekanan kepada komponen kualiti dan keselamatan ubat, akses kepada ubat serta kemampuan mendapat ubat-ubatan telah dipersetujui oleh semua pihak untuk dikekalkan. Isu-isu baru seperti Governance of Medicine serta daya maju dan kemampanan industri farmaseutikal telah dimasukkan ke dalam dasar yang telah disemak semula. Perkongsian dan kerjasama bagi industri penjagaan kesihatan telah dilihat dalam konteks yang lebih makro di mana ia perlu direalisasikan dalam bidang pembangunan sumber manusia, penyelidikan dan pembangunan dan kerjasama teknikal. Perkara lain yang turut diberi perhatian ialah pembangunan dan pelaksanaan amalan-amalan terbaik untuk memastikan penyediaan ubat-ubatan yang berkualiti diimplikasikan di semua peringkat penjagaan kesihatan. Komitmen yang diberikan oleh semua pihak berkepentingan dari sektor awam dan swasta dalam proses penilaian semula telah berjaya menghasilkan Draf DUNas Semakan I. Beberapa bengkel susulan akan dijalankan untuk merangka pelan tindakan bagi 5 tahun seterusnya.

The Pharmaceutical Services Division, Ministry of Health Malaysia held a workshop on the Full Term Review of the Malaysian National Medicines Policy (MNMP) in Holiday Villa & Suites, Subang, Selangor on 15-17 October 2012. The objectives of the workshop were to review on the achievements, shortfalls and relevance of the present strategies which were implemented from end of 2006 – 2012 and to propose new components and strategies for the next 5 years. The workshop involved all stakeholders as their inputs and consensuses are valuable towards the formulation of the policy which we chart the journey for the pharmaceutical sector in the coming years. The workshop was attended by 150 participants from various professional bodies, relevant industry consumer associations, other government agencies and ministries as well as universities.

The essence of the current policy which emphasizes on quality and safety, accessibility and affordability is maintained and agreed upon by all the stakeholders. New issues that are considered pertinent such as the governance of medicines and viability and sustainability of the pharmaceutical industry are regarded as important and therefore included in the revised policy. Partnership and collaboration for the healthcare industry was viewed in a more macro context whereby it should be realised in areas of human resource, research and development and technical cooperation. Another area that needs focus is the development and implementation of best practices to ensure the provision of quality medicines use at all levels of health care. The stakeholders also highlighted that systematic consideration of the practical aspects of implementation is also pertinent to the successful implementation of the policy. The output of the workshop was a draft of the revised policy. Several follow-up workshops will be conducted to fine tune the policy and to formulate the next 5-year plan of action.

Page 18: program farmasi / pharmacy programme

17PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

12 | L a p o r a n T a h u n a n 2 0 1 2

The essence of the current policy which emphasizes on quality and safety, accessibility and

affordability is maintained and agreed upon by all the stakeholders. New issues that are considered

pertinent such as the governance of medicines and viability and sustainability of the pharmaceutical

industry are regarded as important and therefore included in the revised policy. Partnership and

collaboration for the healthcare industry was viewed in a more macro context whereby it should be

realised in areas of human resource, research and development and technical cooperation. Another

area that needs focus is the development and implementation of best practices to ensure the provision

of quality medicines use at all levels of health care. The stakeholders also highlighted that systematic

consideration of the practical aspects of implementation is also pertinent to the successful

implementation of the policy. The output of the workshop was a draft of the revised policy. Several

follow-up workshops will be conducted to fine tune the policy and to formulate the next 5-year plan of

action.

Rajah 2 : Upacara Perasmian Bengkel Kajian Penuh DUNas

Figure 2: Official Launching of DUNas Workshop

13 | L a p o r a n T a h u n a n 2 0 1 2

Rajah 3 : Peserta-Peserta DUNas

Figure 3: DUNas Participants

Rang Undang-Undang Farmasi (RUUF)

New Pharmacy Bill

Bahagian Perkhidmatan Farmasi (BPF) telah bersetuju untuk menggabungkan Akta Pendaftaran Ahli

Farmasi 1951, Akta Racun 1952, Akta Jualan Dadah 1952 dan Akta Ubat (Iklan dan Penjualan) 1956

dalam satu Undang-Undang yang baru. Justeru itu, Rang Undang-Undang Farmasi yang baru (RUUF)

telah digubal untuk mengatasi kelemahan dan lakuna dalam undang-undang yang sedia ada; untuk

mengalakkan keharmonian berpandu dan liberalisasi di kalangan peserta industri; untuk

mengesamengesahkan perjanjian antarabangsa dan konvensyen yang telah ditandatangani oleh

kerajaan; untuk mengenakan hukuman ke atas kesalahan serius dan memperkukuhkan struktur dan

kuasa pihak berkuasa dan peranan pegawai-pegawai penguat kuasa.

BPF telah melaksanakan seranta awam atas talian untuk memastikan ketelusan dan penerimaan

Rang Undang-Undang Farmasi kepada orang ramai termasuk stakeholders. Seranta awam atas talian

tersebut telah dipaparkan di portal KKM dari 16 November 2012 sehingga 7 Disember 2012.

Keputusan daripada seranta awam atas talian tersebut, sebanyak 548 maklumbalas telah diperolehi.

92.67% maklum balas tersebut adalah daripada ahli farmasi swasta; 2.56% daripada ahli farmasi KKM

dan selebihnya adalah dari ahli akademik (0.55%), pengamal perubatan (0.18%), penolong pegawai

farmasi (0.37%), penolong pegawai perubatan (0.18%), NGOs (1.65%), orang ramai (0.18%), industri

(0.18%), pengamal perubatan tradisional (0.92%), kedutaan-kedutaan asing (0.18%) dan agensi-

agensi di bawah KKM (0.37%). Hanya 1.28% membantah pembentangan Rang Undang-Undang

Farmasi tersebut di parlimen.

Page 19: program farmasi / pharmacy programme

18 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

Rang Undang-Undang Farmasi (RUUF) New Pharmacy Bill

Bahagian Perkhidmatan Farmasi (BPF) telah bersetuju untuk menggabungkan Akta Pendaftaran Ahli Farmasi 1951, Akta Racun 1952, Akta Jualan Dadah 1952 dan Akta Ubat (Iklan dan Penjualan) 1956 dalam satu Undang-Undang yang baru. Justeru itu, Rang Undang-Undang Farmasi yang baru (RUUF) telah digubal untuk mengatasi kelemahan dan lakuna dalam undang-undang yang sedia ada; untuk mengalakkan keharmonian berpandu dan liberalisasi di kalangan peserta industri; untuk mengesahkan perjanjian antarabangsa dan konvensyen yang telah ditandatangani oleh kerajaan; untuk mengenakan hukuman ke atas kesalahan serius dan memperkukuhkan struktur dan kuasa pihak berkuasa dan peranan pegawai-pegawai penguat kuasa.

BPF telah melaksanakan seranta awam atas talian untuk memastikan ketelusan dan penerimaan Rang Undang-Undang Farmasi kepada orang ramai termasuk stakeholders. Seranta awam atas talian tersebut telah dipaparkan di portal KKM dari 16 November 2012 sehingga 7 Disember 2012. Keputusan daripada seranta awam atas talian tersebut, sebanyak 548 maklumbalas telah diperolehi. 92.67% maklum balas tersebut adalah daripada ahli farmasi swasta; 2.56% daripada ahli farmasi KKM dan selebihnya adalah dari ahli akademik (0.55%), pengamal perubatan (0.18%), penolong pegawai farmasi (0.37%), penolong pegawai perubatan (0.18%), NGOs (1.65%), orang ramai (0.18%), industri (0.18%), pengamal perubatan tradisional (0.92%), kedutaan-kedutaan asing (0.18%) dan agensi-agensi di bawah KKM (0.37%). Hanya 1.28% membantah pembentangan Rang Undang-Undang Farmasi tersebut di parlimen.

The Pharmaceutical Services Division (PSD) has made the decision to formulate a new law that incorporates the Registration of Pharmacists Act 1951, Poisons Act 1952, Sale of Drugs Act 1952 and the Medicines (Advertisement and Sale) Act 1956 into a new Act. Subsequently, the Pharmacy Bill was drafted, among others, to overcome weaknesses and lacuna in existing legislation; to promote the guided harmonization and liberalization among industry players; to ratify international treaties and conventions which were signed by the state; to impose deterrent penalties on serious offences and to strengthen the structure and power of the competent authority and clarify the role of enforcement officers.

The PSD has implemented an online public engagement to ensure that the Pharmacy Bill is transparent and to engage with the public and other stakeholders. This is a channel to announce and acquire feedback from them. Extracts of the Pharmacy Bill was displayed in the MOH Portal on 16th November 2012 until 7th December 2012. As a result of the online public engagement, a total of 548 feedbacks were received. The respondents were from private pharmacists (92.67%) and 2.56% were from pharmacists in the MOH while the rest were from academia (0.55%), medical practitioners (0.18%), pharmacy assistants (0.37%), medical assistants (0.18%), NGOs (1.65%), public (0.18%), industry (0.18%), traditional medicine practitioners (0.92%), foreign embassies (0.18%) and agencies in the Ministry of Health (0.37%). Only 1.28% of the respondents had protested the tabling of the Bill in the Parliament.

Page 20: program farmasi / pharmacy programme

19PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

4. Persidangan Conferences

Persidangan Perkembangan dan Kajian Farmasi ke-7 20127th Pharmacy R&D Conference 2012

Persidangan ini telah diadakan pada 19-21 Jun 2012 di The Zon Regency Hotel, Johor Bahru. Peserta terdiri daripada ahli farmasi dari KKM, Kementerian Pertahanan, Hospital Universiti dan agensi-agensi awam dan swasta yang lain. Objektif utama persidangan tersebut adalah untuk menggalakkan, mewujudkan wadah untuk berkongsi hasil penyelidikan di kalangan peserta.

This conference was held on 19th to 21st June 2012 at The Zon Regency Hotel, Johor Bahru. Participants were pharmacist, healthcare personnel from Ministry of Health, Ministry of Defense, University Hospitals and other public and private agencies. The conference was to encourage and create a platform to share research findings among the participants.

15 | L a p o r a n T a h u n a n 2 0 1 2

Rajah 4 : Upacara Perasmian Persidangan Perkembangan dan Kajian Farmasi ke-7 2012

Figure 4 :Official Launching of 7th Pharmacy R&D Conference 2012

Rajah 5 : Peserta menjelaskan penyelidikan kepada mantan Ketua Pengarah Kesihatan (KPK)

Figure 5: Briefing of Ex-Director General of Health by Participant

Pharmacy Practice Scientific Conference

Pharmacy Practice Scientific Conference (PPSC) telah diadakan pada 24 - 25 Mac 2012 di Hotel

Istana, Kuala Lumpur dengan tema : Pharmacy Specialization: Achieving Excellence. Sehubungan itu,

empat orang ahli farmasi yang mempunyai kepakaran dalam pelbagai bidang dari Amerika Syarikat

telah dijemput untuk menjayakan bengkel persediaan menghadapi peperiksaan Board of Pharmacy

Specialties. Seramai 17 orang Pegawai Farmasi KKM telah lulus di dalam peperiksaan tersebut yang

dikendalikan oleh American College of Clinical Pharmacy.

15 | L a p o r a n T a h u n a n 2 0 1 2

Rajah 4 : Upacara Perasmian Persidangan Perkembangan dan Kajian Farmasi ke-7 2012

Figure 4 :Official Launching of 7th Pharmacy R&D Conference 2012

Rajah 5 : Peserta menjelaskan penyelidikan kepada mantan Ketua Pengarah Kesihatan (KPK)

Figure 5: Briefing of Ex-Director General of Health by Participant

Pharmacy Practice Scientific Conference

Pharmacy Practice Scientific Conference (PPSC) telah diadakan pada 24 - 25 Mac 2012 di Hotel

Istana, Kuala Lumpur dengan tema : Pharmacy Specialization: Achieving Excellence. Sehubungan itu,

empat orang ahli farmasi yang mempunyai kepakaran dalam pelbagai bidang dari Amerika Syarikat

telah dijemput untuk menjayakan bengkel persediaan menghadapi peperiksaan Board of Pharmacy

Specialties. Seramai 17 orang Pegawai Farmasi KKM telah lulus di dalam peperiksaan tersebut yang

dikendalikan oleh American College of Clinical Pharmacy.

Page 21: program farmasi / pharmacy programme

20 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

16 | L a p o r a n T a h u n a n 2 0 1 2

The Pharmacy Practice Scientific Conference (PPSC) was held on the 24th-25

th March 2012 at Hotel

Istana, Kuala Lumpur with the theme of Pharmacy Specializations: Achieving Excellence. In tandem

with the theme of the conference, 4 specialist pharmacists from the United States of America were

invited to assist the preparation workshop for the Board of Pharmacy Specialists Examination. A total

of 17 MOH pharmacists have passed the exam that was organized by the American College of Clinical

Pharmacy.

5. Pelancaran Program Duta Kenali Ubat Anda

Official Launching of Know Your Medicine Ambassador

Programme

Program ini telah dilancarkan pada 11 Mei 2012 di Kota Bharu, Kelantan. Di antara objektif program

yang telah dijalankan ini adalah untuk menggalakkan penglibatan aktif pengguna di dalam aktiviti

penggunaan ubat berkualiti, meningkatkan pengetahuan dan kemahiran pengguna agar mereka

mampu membuat keputusan berkenaan penjagaan kesihatan mereka, penerapan konsep

empowerment di dalam pengubatan di kalangan masyarakat Malaysia dan juga untuk membentuk

rangkaian individu di dalam komuniti yang bertindak sebagai wakil kesihatan masyarakat yang

menyokong penggunaan ubat secara berkualiti.

This programme was launched on 11th of May 2012 in Kota Bharu, Kelantan. Among the objectives of

the programme were to promote quality use of medicines among consumers, increasing consumer

knowledge and skills so that they can make decisions about their health care, incorporate the concept

of empowerment in medication and also to form network of individuals in the community who act as

representatives that support quality use of medicines.

Rajah 6: Modul Program Rajah 7: Majlis Pelancaran Figure 6: Programme Module Figure 7: Official Launching

Pharmacy Practice Scientific Conference

Pharmacy Practice Scientific Conference (PPSC) telah diadakan pada 24 - 25 Mac 2012 di Hotel Istana, Kuala Lumpur dengan tema : Pharmacy Specialization: Achieving Excellence. Sehubungan itu, empat orang ahli farmasi yang mempunyai kepakaran dalam pelbagai bidang dari Amerika Syarikat telah dijemput untuk menjayakan bengkel persediaan menghadapi peperiksaan Board of Pharmacy Specialties. Seramai 17 orang Pegawai Farmasi KKM telah lulus di dalam peperiksaan tersebut yang dikendalikan oleh American College of Clinical Pharmacy.

The Pharmacy Practice Scientific Conference (PPSC) was held on the 24th-25th March 2012 at Hotel Istana, Kuala Lumpur with the theme of Pharmacy Specializations: Achieving Excellence. In tandem with the theme of the conference, 4 specialist pharmacists from the United States of America were invited to assist the preparation workshop for the Board of Pharmacy Specialists Examination. A total of 17 MOH pharmacists have passed the exam that was organized by the American College of Clinical Pharmacy.

5. Pelancaran Program Duta Kenali Ubat Anda Official Launching of Know Your Medicine Ambassador Programme

Program ini telah dilancarkan pada 11 Mei 2012 di Kota Bharu, Kelantan. Di antara objektif program yang telah dijalankan ini adalah untuk menggalakkan penglibatan aktif pengguna di dalam aktiviti penggunaan ubat berkualiti, meningkatkan pengetahuan dan kemahiran pengguna agar mereka mampu membuat keputusan berkenaan penjagaan kesihatan mereka, penerapan konsep empowerment di dalam pengubatan di kalangan masyarakat Malaysia dan juga untuk membentuk rangkaian individu di dalam komuniti yang bertindak sebagai wakil kesihatan masyarakat yang menyokong penggunaan ubat secara berkualiti.

This programme was launched on 11th of May 2012 in Kota Bharu, Kelantan. Among the objectives of the programme were to promote quality use of medicines among consumers, increasing consumer knowledge and skills so that they can make decisions about their health care, incorporate the concept of empowerment in medication and also to form network of individuals in the community who act as representatives that support quality use of medicines.

Page 22: program farmasi / pharmacy programme

21PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

6. Penerbitan Bahagian Perkhidmatan Farmasi Pharmaceutical Services Division Publications

Antara penerbitan yang telah dikeluarkan dan diedarkan sepanjang tahun 2012 di fasiliti KKM adalah 3 protokol, 2 flipchart, 4 risalah dan 15 garis panduan.

Sebanyak 3 edisi Berita Ubat-Ubatan (majalah mengenai polisi PBKD), 3 edisi Buletin MADRAC (Malaysian Adverse Drug Reactions Advisory Committee) dan satu naskah Laporan Tahunan BPFK telah diterbitkan untuk edaran pada tahun 2012.

Among the publications that were produced and circulated throughout MOH facilities in the year 2012 were 3 protocols, 2 flipcharts, 4 pamphlets and 15 guidelines.

A total of 3 editions of Berita Ubat-Ubatan (magazine concerning DCA policies) and 3 editions of the MADCRAC Bulletin (Malaysian Adverse Drug Reactions Advisory Committee Bulletin) were published in the year 2012, along with one edition of the NPCB Annual report.

17 | L a p o r a n T a h u n a n 2 0 1 2

6. Penerbitan Bahagian Perkhidmatan Farmasi Pharmaceutical Services Division Publications Antara penerbitan yang telah dikeluarkan dan diedarkan sepanjang tahun 2012 di fasiliti KKM adalah 3

protokol, 2 flipchart, 4 risalah dan 15 garis panduan.

Sebanyak   3   edisi   Berita   Ubat-­‐Ubatan   (majalah   mengenai   polisi   PBKD),   3   edisi   Buletin   MADRAC  

(Malaysian   Adverse   Drug   Reactions   Advisory   Committee)   dan   satu   naskah   Laporan   Tahunan   BPFK  

telah  diterbitkan  untuk  edaran  pada  tahun  2012.  

Among the publications that were produced and circulated throughout MOH facilities in the year 2012

were 3 protocols, 2 flipcharts, 4 pamphlets and 15 guidelines.

A total of 3 editions of Berita Ubat-Ubatan (magazine concerning DCA policies) and 3 editions of the

MADCRAC Bulletin (Malaysian Adverse Drug Reactions Advisory Committee Bulletin) were published

in the year 2012, along with one edition of the NPCB Annual report.  

Jadual 10: Jenis Penerbitan Yang Dikeluarkan

Table 10: Types of Publications Produced

 Bil.    No.  

 Jenis  Penerbitan  

Type  of  Publication  

 Tajuk  Penerbitan  Title  of  Publication  

 

1  Protokol  Protocol  

Home  Medication  Review  Protocol  Buku  Rawatan  Antikoagulasi  (Warfarin)  Anticoagulation  Treatment  Book  (Warfarin)  Protokol  Medication  Therapy  Adherence  Clinic:  Psikiatri  

2   Flipchart  

Modul  Pendidikan  Pesakit  bagi  perkhidmatan  DMTAC  Patient  Education  Module  for  DMTAC  Service  Kaunseling  pesakit  HIV/AIDS  Counselling  HIV/AIDS  Patients  

3  Risalah  

Pamphlet  

Memahami  jangkitan  HIV  Understanding  HIV  Infection  Memahami  ubat  Anti  Retroviral  (HAART)  Understanding  Anti-­‐Retroviral  Medications  (HAART)  

  Kalendar  Bermesej  Messages  Calendar  

    What  Prescribers  Should  Know  About  Generic  Medicines  

Page 23: program farmasi / pharmacy programme

22 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

18 | L a p o r a n T a h u n a n 2 0 1 2

4  

Garis  Panduan  &  

Modul  latihan  Guidelines  &  Training  Modules  

Modul  latihan  Medication  Therapy  Adherence  Clinic  (MTAC)  Warfarin  Medication  Therapy  Adherence  Clinic  (MTAC)  Warfarin  Training  Module  Modul  latihan  Wad  Farmasi  Ward  Pharmacy  Training  Module  Modul  latihan  Respiratory  MTAC  In  Adult  Asthma  &  COPD  Pharmacist  Training  Module  for  Respiratory  MTAC  In  Adult  Asthma  &  COPD  Modul  latihan  Parenteral  Nutrition  1st  Edition  Pharmacist  Training  Module  Parenteral  Nutrition  1st  Edition  Pharmacist  Training  Logbook  Medication  Therapy  Adherence  Clinic  (MTAC):  Diabetes  Mellitus  Modul  Program  Kenali  Duta  Ubat  Anda  Know  Your  Medicine  Ambassador  Program  Module  Garis  panduan  kaunseling  ubat-­‐ubatan  Counselling  Guidelines  of  Medicines  Garis  panduan  Pemeriksaan  Premis  Guidelines  on  Premises  Inspection  Cross  Reference  for  Export-­‐Controlled  Chemicals  Garis  panduan  Penggendalian  Aduan  Guidelines  on  Handling  Complaints  Garis  panduan  Siasatan  untuk  Pegawai  Penguatkuasa  Farmasi,  Kementerian  Kesihatan  Malaysia  Investigation  Guidelines  for  Enforcement  Officers,  Ministry  of  Health  Garis  panduan  Pelupusan  Barang  Rampasan/  Ekshibit  Guidelines  on  Disposal  of  Confiscated  Goods/  Exhibits  Garis  panduan  Menutup  Kertas  Siasatan  Tanpa  Tindakan  Lanjut  Guidelines  on  Closing  Investigation  Papers  without  Further  Action  Garis  panduan  Pengendalian  Ekshibit  dan  Stor  Ekshibit  Cawangan  Penguatkuasaan  Farmasi,  Kementerian  Kesihatan  Malaysia    Guidelines  on  Handling  Exhibits  and  Exhibits  Store  for  Enforcement  Pharmacy,  Ministry  of  Health  Kompilasi  Contoh-­‐Contoh  Pertuduhan  bagi  Akta  Racun  1952,  Akta  Jualan  Dadah  1952  dan  Akta  Pendaftaran  Ahli  Farmasi  1951  Compilation  of  example  of  charges  of  Poisons  Act  1952,  Sale  of  Drugs  Act  1952  and  Registration  of  Pharmacists  Act  1951  

 

Page 24: program farmasi / pharmacy programme

23PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

Data bagi Senarai Harga Ubat 2012 telah disediakan untuk penerbitan pada Disember 2012. Senarai harga ubat-ubatan ini boleh diakses dengan mudah oleh orang ramai di laman web rasmi BPF (www.pharmacy.gov.my).

Unit Proforma telah menyediakan garis panduan sebagai rujukan kepada semua fasiliti KKM dalam menggunakan ubat-ubatan yang terdapat di dalam dan juga di luar FUKKM. Antara kandungan yang terdapat di dalam garis panduan ini adalah:

i. Prosedur penyenaraian ubat ke dalam FUKKMii. Pengenalan terhadap Senarai Ubat Penting Kebangsaan atau National Essential Drug List

(NEDL), sekarang dikenali sebagai National Essential Medicines List (NEML)iii. Prosedur permohonan ubat khas Ketua Pengarah Kesihatan (KPK) dan Pengarah Kanan

Perkhidmatan Farmasi (PKPF)iv. Borang proforma dan KPKv. Terma rujukan Jawatankuasa Kerja Ubat di peringkat kesihatan, hospital dan negeri.

Buku garis panduan ini telah diedarkan kepada semua fasiliti KKM di seluruh negara.

The Medicines Price List of 2012 data was made available for publication by December 2012. This list can be easily accessed through the official PSD website. (www.pharmacy.gov.my)

The Proforma Unit has prepared a guideline as reference to all MOH facilities in using medicines listed in and out of the Formulary. Among the contents of the guidelines are:

i. Procedure in listing a medicines into the MOH medicines formularyii. Introduction to the National Essential Drug List (NEDL), now known as National Essential

Medicines List (NEML)iii. Procedure for aplication of special approval medicines by the Director General of Health

and Senior Director of Pharmaceutical Services Divisioniv. Proforma and special approval medicines formsv. Terms of reference for the Therapeutic Drug Working Committee in the health, hospital and

state.

This guideline has been circulated to all the MOH facilities in the country.

20 | L a p o r a n T a h u n a n 2 0 1 2

Rajah 8 : Senarai Harga Ubat yang Dikeluarkan pada Tahun 2012 (Cetakan 2013)

Figure 8 : Medicines Price List (Printed 2013)

7. KAJIAN PENGGUNAAN UBAT KEBANGSAAN

NATIONAL MEDICINES USE SURVEY

Projek Kajian Penggunaan Ubat Kebangsaan (NMUS) telah dimulakan pada tahun 2005 oleh Pusat

Penyelidikan Klinikal (CRC) dengan kerjasama Bahagian Perkhidmatan Farmasi (BPF). Mulai bulan

September 2006, pengurusan NMUS telah diambil alih oleh BPF manakala CRC mengendalikan

aspek pelaksanaan kajian dan khidmat statistik. NMUS dilaksanakan secara berterusan bagi mengkaji

penggunaan ubat-ubatan di negara ini yang dijangka berubah mengikut masa. Berikut merupakan

objektif NMUS:

i. Untuk mengetahui jenis dan jumlah ubat-ubat yang dibekalkan di Malaysia. Ini penting untuk

mengukur tahap penggunaan dan perbelanjaan ubat-ubatan di negara ini.

ii. Untuk mengetahui jenis dan jumlah ubat-ubatan yang dipreskrib dan/atau didispen di

Malaysia. Ia penting untuk mengetahui kualiti preskripsi dan amalan pendispensan di negara

ini.

iii. Untuk mengetahui jenis dan jumlah ubat-ubatan yang digunakan oleh pengguna-pengguna di

Malaysia. Ia penting untuk mengukur pola penggunaan ubat-ubatan bagi tujuan menilai

penggunaan ubat secara rasional oleh pengguna di dalam negara ini.

iv. Untuk menggalakkan dan memudahkan kajian berkaitan penggunaan ubat-ubatan.

Bagi memperolehi data di pelbagai peringkat sistem pembekalan dan pengedaran ubat di negara ini

(termasuk fasiliti kesihatan awam dan swasta), NMUS perlu menjalankan beberapa kajian secara

sistematik. Data telah dikumpul dengan menggunakan kaedah-kaedah berikut:

Page 25: program farmasi / pharmacy programme

24 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

7. KAJIAN PENGGUNAAN UBAT KEBANGSAAN NATIONAL MEDICINES USE SURVEY

Projek Kajian Penggunaan Ubat Kebangsaan (NMUS) telah dimulakan pada tahun 2005 oleh Pusat Penyelidikan Klinikal (CRC) dengan kerjasama Bahagian Perkhidmatan Farmasi (BPF). Mulai bulan September 2006, pengurusan NMUS telah diambil alih oleh BPF manakala CRC mengendalikan aspek pelaksanaan kajian dan khidmat statistik. NMUS dilaksanakan secara berterusan bagi mengkaji penggunaan ubat-ubatan di negara ini yang dijangka berubah mengikut masa. Berikut merupakan objektif NMUS:

• Untuk mengetahui jenis dan jumlah ubat-ubat yang dibekalkan di Malaysia. Ini penting untuk mengukur tahap penggunaan dan perbelanjaan ubat-ubatan di negara ini.

• Untuk mengetahui jenis dan jumlah ubat-ubatan yang dipreskrib dan/atau didispen di Malaysia. Ia penting untuk mengetahui kualiti preskripsi dan amalan pendispensan di negara ini.

• Untuk mengetahui jenis dan jumlah ubat-ubatan yang digunakan oleh pengguna-pengguna di Malaysia. Ia penting untuk mengukur pola penggunaan ubat-ubatan bagi tujuan menilai penggunaan ubat secara rasional oleh pengguna di dalam negara ini.

• Untuk menggalakkan dan memudahkan kajian berkaitan penggunaan ubat-ubatan.

Bagi memperolehi data di pelbagai peringkat sistem pembekalan dan pengedaran ubat di negara ini (termasuk fasiliti kesihatan awam dan swasta), NMUS perlu menjalankan beberapa kajian secara sistematik. Data telah dikumpul dengan menggunakan kaedah-kaedah berikut:

• Muat turun daripada pangkalan data sedia ada seperti pangkalan data perolehan ubat-ubatan hospital

• Pengutipan data primer untuk kajian pendispensan

Pencapaian NMUS pada tahun 2012 adalah seperti di Jadual 11. Hasil pelaksanaan NMUS, lima laporan Malaysian Statistics on Medicines (MSOM) telah berjaya diterbitkan, bagi tahun 2004 hingga 2008 yang boleh dicapai melalui laman web BPF (www.pharmacy.gov.my) dan CRC (www.crc.gov.my). Penerbitan Laporan MSOM 2009 dan 2010 akan diterbitkan pada awal tahun 2014.

Laporan-laporan yang dijana amat berguna dalam menyediakan data awal berkaitan penggunaan ubat-ubatan di negara ini dan boleh dijadikan sebagai asas untuk tindakan lanjut apabila diperlukan. Sebagai contoh, ia boleh digunakan bagi membuat keputusan yang lebih baik dalam menggunakan peruntukan sumber-sumber untuk penjagaan kesihatan di Malaysia. Data ini juga boleh digunakan untuk membandingkan corak penggunaan ubat-ubatan di Malaysia dengan negara-negara maju. Ia penting bagi memantau seterusnya meningkatkan kualiti penggunaan ubat ke arah rawatan yang lebih kos-efektif selaras dengan objektif Dasar Ubat Nasional (DUNas).

Page 26: program farmasi / pharmacy programme

25PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

The National Medicines Use Survey (NMUS) which was initiated in 2005 is a research project jointly sponsored by the Pharmaceutical Services Division (PSD) and Clinical Research Centre (CRC). From the beginning of September 2006, PSD undertook the role of the primary sponsor for the NMUS while CRC remained as an important collaborating unit that provides research and statistical support. NMUS is conducted continuously to study the utilization of medicines in the country which is expected to change over time. The objectives of NMUS are:

• To know the types and amount of medicines supplied in Malaysia. These are useful in measuring the utilization and the expenditure level of medicines in the country.

• To know the types and amount of medicines prescribed and/or dispensed in Malaysia. These are useful measures for the quality of prescription and dispensing practices in the country.

• To know the types and amount of medicines consumed by consumers in Malaysia. These are useful measures for the pattern of use of medicines in order to evaluate its rational use by consumers in the country.

• To stimulate and facilitate researches on use of medicines.

In order to capture data at various levels of the medicines supply and distribution system in the country (including government and private healthcare facilities), NMUS has to conduct several surveys systemically. The following methods are used to collect these data:

• Download from existing databases, for example hospital’s pharmaceutical procurement databases

• Primary data collection for dispensing survey • The achievements of NMUS for the year 2012 are summarized in Table 11. As a

result of the implementation of NMUS, four reports entitled Malaysian Statistics on Medicines (MSOM) have been published for the year 2004 until 2008, which are accessible through the websites of PSD (www.pharmacy.gov.my) and CRC (www.crc.gov.my). The report for MSOM 2009 and 2010 will be published in early 2014.

These generated reports have been useful in providing preliminary data on medicines use in the country and can be used as a basis for further actions, if necessary. For example, it can be used as a tool for better decision making in the allocation of healthcare resources for the Malaysian population. These data can also be used for comparison on drug usage pattern with developed countries. This effort is important for monitoring to increase the quality of drug usage towards a more cost effective treatment. This is in accordance with the objectives of the Malaysian National Medicines Policy (NMP).

Page 27: program farmasi / pharmacy programme

26 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

22 | L a p o r a n T a h u n a n 2 0 1 2

iii. The achievements of NMUS for the year 2012 are summarized in Table 11. As a result of the

implementation of NMUS, four reports entitled Malaysian Statistics on Medicines (MSOM)

have been published for the year 2004 until 2008, which are accessible through the websites

of PSD (www.pharmacy.gov.my) and CRC (www.crc.gov.my). The report for MSOM 2009 and

2010 will be published in early 2014.

These generated reports have been useful in providing preliminary data on medicines use in the

country and can be used as a basis for further actions, if necessary. For example, it can be used as a

tool for better decision making in the allocation of healthcare resources for the Malaysian population.

These data can also be used for comparison on drug usage pattern with developed countries. This

effort is important for monitoring to increase the quality of drug usage towards a more cost effective

treatment. This is in accordance with the objectives of the Malaysian National Medicines Policy (NMP).

Rajah 9 : Peserta-peserta NMUS Rajah 10 : Laporan MSOM

Figure 9: NMUS Participants Figure 10: MSOM Report

23 | L a p o r a n T a h u n a n 2 0 1 2

Jadual 11: Pencapaian NMUS dalam Tahun 2012

Table 11: Achievement of NMUS in 2012

Bil.

No.

Aktiviti

Activities

Output

Output

Pencapaian

Achievements

1.

Pelaksanaan berterusan projek NMUS dengan usaha sama CRC.

Continuous implementation of NMUS project in collaboration with CRC.

Penerbitan Malaysian Statistics on Medicines (MSOM).

Publication of the Malaysian Statistics on Medicines (MSOM).

MSOM 2008:

Telah diterbitkan pada Mei 2013.

MSOM 2008:

Published in May 2013.

2. Pembangunan aplikasi client-server untuk kemasukan data pendispensan ubat. Development of a client-server application to enter dispensing data.

Aplikasi “NMUS Data Entry (Retail Pharmacy)”. “NMUS Data Entry (Retail Pharmacy)” Application.

1 aplikasi.

1 application.

8. Aktiviti Pembangunan Sistem System Development Activities Sepanjang tahun 2012, Bahagian Perkhidmatan Farmasi, KKM telah menitikberatkan pembangunan

Sistem Maklumat Farmasi Hospital (PhIS) dan sistem maklumat farmasi klinik (CPS). Projek ini memberi

tumpuan kepada aktiviti pembangunan 12 modul dalam sistem dan pencapaian sehingga 31 Disember

2012 adalah seperti di Jadual 12.

Sebanyak 14 aktiviti seperti bengkel penyediaan, semakan, lawatan dan mesyuarat telah diadakan

bagi mengesahkan keperluan pengguna sebelum dokumen User Requirement Specification (URS)

dan System Design Documentation (SDD) dimuktamadkan.

Selain pembangunan sistem, aktiviti persediaan pelaksanaan di fasiliti perintis telah dijalankan dengan

pesatnya seperti di Jadual 13. Ini bagi memastikan setiap fasiliti bersedia dari segi infrastruktur dan

pengguna ke arah melaksanakan sistem ini di fasiliti masing-masing.

Page 28: program farmasi / pharmacy programme

27PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

8. Aktiviti Pembangunan Sistem System Development Activities

Sepanjang tahun 2012, Bahagian Perkhidmatan Farmasi, KKM telah menitikberatkan pembangunan Sistem Maklumat Farmasi Hospital (PhIS) dan sistem maklumat farmasi klinik (CPS). Projek ini memberi tumpuan kepada aktiviti pembangunan 12 modul dalam sistem dan pencapaian sehingga 31 Disember 2012 adalah seperti di Jadual 12.

Sebanyak 14 aktiviti seperti bengkel penyediaan, semakan, lawatan dan mesyuarat telah diadakan bagi mengesahkan keperluan pengguna sebelum dokumen User Requirement Specification (URS) dan System Design Documentation (SDD) dimuktamadkan.

Selain pembangunan sistem, aktiviti persediaan pelaksanaan di fasiliti perintis telah dijalankan dengan pesatnya seperti di Jadual 13. Ini bagi memastikan setiap fasiliti bersedia dari segi infrastruktur dan pengguna ke arah melaksanakan sistem ini di fasiliti masing-masing.

Peruntukan perkakasan telah dimuktamadkan semasa mesyuarat pelaksanaan infrastruktur di fasiliti perintis. Selain itu pengguna juga diperkenalkan dengan konsep ADKAR (Awareness, Desire, Knowledge, Ability, Reinforcement) semasa Program Pengurusan Perubahan dijalankan.

In 2012, PSD has emphasized on the importance of the development of the Pharmacy Hospital Information System (PHIS) and the Clinical Pharmacy Information System (CPS). This project focused on the development of 12 modules in the system throughout the year 2012. Achievements of system development until 31 December 2012 are shown in Table 12.

A total of 14 activities such as workshops, reviews, visits and meetings were held to validate and verify the user requirements before finalizing the User Requirement Specification (URS) document and System Design Documentation (SDD).

Besides system development, implementation readiness and preparation activities were conducted extensively at pilot facilities as shown in Table 13. This is to ensure that all facilities have adequate infrastructure ensure and user-readiness towards implementing the system in their facilities.

Allocation of hardware was finalized during the Infrastructure Implementation Meeting held at each pilot facility. Apart from that, users were also introduced with ADKAR (Awareness, Desire, Knowledge, Ability, Reinforcement) concept during the Change Management Program at facility.

Page 29: program farmasi / pharmacy programme

28 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

24 | L a p o r a n T a h u n a n 2 0 1 2

In 2012, PSD has emphasized on the importance of the development of the Pharmacy Hospital

Information System (PHIS) and the Clinical Pharmacy Information System (CPS). This project focused

on the development of 12 modules in the system throughout the year 2012. Achievements of system

development until 31 December 2012 are shown in Table 12.

A total of 14 activities such as workshops, reviews, visits and meetings were held to validate and verify

the user requirements before finalizing the User Requirement Specification (URS) document and

System Design Documentation (SDD).

Besides system development, implementation readiness and preparation activities were conducted

extensively at pilot facilities as shown in Table 13. This is to ensure that all facilities have adequate

infrastructure ensure and user-readiness towards implementing the system in their facilities.

Allocation of hardware was finalized during the Infrastructure Implementation Meeting held at each

pilot facility. Apart from that, users were also introduced with ADKAR (Awareness, Desire, Knowledge,

Ability, Reinforcement) concept during the Change Management Program at facility.

Jadual 12: Aktiviti Pembangunan Sistem

Table 12: System Development Activities

Bil. No.

Aktiviti

Activities

Pencapaian Achievements

1

Mesyuarat KICK OFF untuk memulakan projek Kick OFF Meeting to start the project

Project Initiation Document (PID) v1.2 dan project plan v.3.2 disahkan oleh Project Implementation Technical Committee (PITC). Project Initiation Document (PID) v1.2 and project plan v.3.2 were endorsed by Project Implementation Technical Committee (PITC)

2

Bengkel Penyediaan dan Pengesahan keperluan pengguna (4 sesi) Workshop on Preparation and Verification on User Requirements (4 session)

User Requirement Specification (URS) v1.3 dimuktamadkan pada 15 Februari 2012 User Requirement Specification (URS) v1.3 was finalized on 15 Feb 2012

3

Bengkel Semakan Rekabentuk Sistem (2 sesi) Workshop on System Design Review (2 session)

System Design Documentation (SDD) v1.2 dimuktamadkan pada 12 Apr 2012 System Design Documentation (SDD) v1.2 was finalized on 12 Apr 2012

4

Bengkel/Mesyuarat Pembangunan Data (8 sesi) Workshop/ meetings on Data Preparation and Development (8 session)

Spesifikasi data ubat dan bukan ubat telah dimuktamadkan pada Julai 2012. Proses validasi data dijalankan secara berterusan sehingga pembangunan sistem selesai. Drug and non drug data specifications was finalized on July 2012. Data validation process will be carried out continously until system development is completed.

Page 30: program farmasi / pharmacy programme

29PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

25 | L a p o r a n T a h u n a n 2 0 1 2

Jadual 13: Aktiviti Persediaan Pelaksanaan di Fasiliti Perintis

Table 13: Implementation Readiness/Preparation Activities at Pilot Facilities

Bil. No.

Aktiviti Activities

Pencapaian Achievements

1

Majlis Dialog dan Kunjungan Hormat di Fasiliti Perintis Dialogue session and Courtesy visit at Pilot Facilities

i) Kunjungan hormat di PKD Kinta : 18 April 2012 i) Courtesy visit at PKD Kinta : 18 April 2012 ii) Majlis Dialog di Hospital Pakar Sultanah Fatimah, Muar : 11 Jun 2012 ii) Dialogue session at Hospital Pakar Sultanah Fatimah, Muar : 11 June 2012 iii) Kunjungan hormat di JKN Perak : 30 November 2012 iii) Courtesy visit at JKN Perak : 30 November 2012 iv) Kunjungan hormat di JKN Kelantan : 3 Disember 2012 iv) Courtesy visit at JKN Kelantan : 3 December 2012 v) Kunjungan hormat di JKN Sarawak : 19 Disember 2012 v) Courtesy visit at JKN Sarawak : 19 December 2012 vi) Majlis Dialog di Hospital Miri, Sarawak : 20 Disember 2012 vi) Dialogue session at Hospital Miri, Sarawak : 20 December 2012

2

Program Pengurusan Perubahan di Ibu Pejabat dan fasiliti pilot Change Management Program at Headquarters and Pilot Facilities

i) Mesyuarat penyediaan dan semakan kandungan Program Pengurusan Perubahan - 4 Mei, 7 Mei, 16 Mei, 21-22 Mei, 28 Jun dan 4 Julai 2012 i) Meeting for preparation and content review for Change Management Program - 4 May, 7 May, 16 May, 21-22 May, 28 June dan 4 July 2012 ii) Bengkel Pengurusan Perubahan di HPSF, Muar : 7 Julai 2012 ii) Change Management Workshop at HPSF, Muar : 7 July 2012 iii) Bengkel Pengurusan Perubahan di PKD Kinta : 13 September 2012 iii) Change Management Workshop at PKD Kinta : 13 September 2012 iv) Bengkel Pengurusan Perubahan di Hospital Seri Manjung : 5 Disember 2012 iv) Change Management Workshop at Hospital Seri Manjung : 5 December 2012

25 | L a p o r a n T a h u n a n 2 0 1 2

Jadual 13: Aktiviti Persediaan Pelaksanaan di Fasiliti Perintis

Table 13: Implementation Readiness/Preparation Activities at Pilot Facilities

Bil. No.

Aktiviti Activities

Pencapaian Achievements

1

Majlis Dialog dan Kunjungan Hormat di Fasiliti Perintis Dialogue session and Courtesy visit at Pilot Facilities

i) Kunjungan hormat di PKD Kinta : 18 April 2012 i) Courtesy visit at PKD Kinta : 18 April 2012 ii) Majlis Dialog di Hospital Pakar Sultanah Fatimah, Muar : 11 Jun 2012 ii) Dialogue session at Hospital Pakar Sultanah Fatimah, Muar : 11 June 2012 iii) Kunjungan hormat di JKN Perak : 30 November 2012 iii) Courtesy visit at JKN Perak : 30 November 2012 iv) Kunjungan hormat di JKN Kelantan : 3 Disember 2012 iv) Courtesy visit at JKN Kelantan : 3 December 2012 v) Kunjungan hormat di JKN Sarawak : 19 Disember 2012 v) Courtesy visit at JKN Sarawak : 19 December 2012 vi) Majlis Dialog di Hospital Miri, Sarawak : 20 Disember 2012 vi) Dialogue session at Hospital Miri, Sarawak : 20 December 2012

2

Program Pengurusan Perubahan di Ibu Pejabat dan fasiliti pilot Change Management Program at Headquarters and Pilot Facilities

i) Mesyuarat penyediaan dan semakan kandungan Program Pengurusan Perubahan - 4 Mei, 7 Mei, 16 Mei, 21-22 Mei, 28 Jun dan 4 Julai 2012 i) Meeting for preparation and content review for Change Management Program - 4 May, 7 May, 16 May, 21-22 May, 28 June dan 4 July 2012 ii) Bengkel Pengurusan Perubahan di HPSF, Muar : 7 Julai 2012 ii) Change Management Workshop at HPSF, Muar : 7 July 2012 iii) Bengkel Pengurusan Perubahan di PKD Kinta : 13 September 2012 iii) Change Management Workshop at PKD Kinta : 13 September 2012 iv) Bengkel Pengurusan Perubahan di Hospital Seri Manjung : 5 Disember 2012 iv) Change Management Workshop at Hospital Seri Manjung : 5 December 2012

26 | L a p o r a n T a h u n a n 2 0 1 2

3

Persediaan Pelaksanaan Infrastruktur di Fasiliti Pilot Infrastructure Implementation Readiness at Pilot Facilities

i) Mesyuarat Pelaksanaan Infrastruktur di HPSF, Muar : 3 September 2012

i) Infrastructure Implementation Meeting at HPSF, Muar : 3 September 2012 ii) Mesyuarat Pelaksanaan Infrastruktur di PKD Kinta : 12 September 2012

ii) Infrastructure Implementation Meeting at PKD Kinta : 12 September 2012 iii) Mesyuarat Pelaksanaan Infrastruktur di Hosp. Seri Manjung: 6 Disember 2012 iii) Infrastruture Implementation Meeting at Hosp. Seri Manjung: 6 December 2012 iv) Mesyuarat Pelaksanaan Infrastruktur di Hosp. Tanah Merah: 23 Disember 2013 iv) Infrastructure Implementation Meeting at Hosp. Tanah Merah: 23 December 2013

Sistem Pengurusan dan Kawalan Substan (SPIKES)

Integrated Substance Control Management System (SPIKES)

SPIKES (www.myspikes.gov.my) ialah satu sistem pengurusan dan kawalan substan yang

dibangunkan hasil dari sub-inisiatif Pengekangan Bekalan Dadah (Drug Supply Suppression) di

bawah inisiatif mengurangkan kadar jenayah jalanan di bawah Makmal Jenayah NKRA. SPIKES

mengintegrasikan kawalan substan (bahan-bahan narkotik, bahan-bahan psikotropik dan kimia

prekursor) dengan kolaborasi perkongsian maklumat substan dengan agensi-agensi kerajaan yang

menguatkuasakan kawalan dadah negara seperti Agensi Anti Dadah Kebangsaan (AADK), Polis

DiRaja Malaysia (PDRM), Kastam DiRaja Malaysia (KDRM), Jabatan Kimia Malaysia (JKM) dan

Bahagian Perkhidmatan Farmasi, Kementerian Kesihatan Malaysia (BPF KKM). Sebagai pihak

berkuasa berwibawa (competent authority) kawalan substan di negara ini, BPF KKM telah dilantik

sebagai agensi peneraju bagi menjalankan inisiatif SPIKES ini.

Sistem Pengurusan Integrasi Kawalan Efektif Substan (SPIKES) telah dilancarkan di Dewan

Anggerik, Biro Pengawalan Farmaseutikal Kebangsaan KKM pada 23 Februari 2012.

SPIKES is a system that is used in the management and control of substances. It was developed as

an outcome of the Drug Supply Suppression sub-initiative of the National Key Results Area (NKRA)

Crime Lab under the Government Transformation Programme (GTP). SPIKES integrates control of

substances (narcotics, psychotropic substances and precursor chemicals) and facilitates substance

Page 31: program farmasi / pharmacy programme

30 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

Sistem Pengurusan dan Kawalan Substan (SPIKES)Integrated Substance Control Management System (SPIKES)

SPIKES (www.myspikes.gov.my) ialah satu sistem pengurusan dan kawalan substan yang dibangunkan hasil dari sub-inisiatif Pengekangan Bekalan Dadah (Drug Supply Suppression) di bawah inisiatif mengurangkan kadar jenayah jalanan di bawah Makmal Jenayah NKRA. SPIKES mengintegrasikan kawalan substan (bahan-bahan narkotik, bahan-bahan psikotropik dan kimia prekursor) dengan kolaborasi perkongsian maklumat substan dengan agensi-agensi kerajaan yang menguatkuasakan kawalan dadah negara seperti Agensi Anti Dadah Kebangsaan (AADK), Polis DiRaja Malaysia (PDRM), Kastam DiRaja Malaysia (KDRM), Jabatan Kimia Malaysia (JKM) dan Bahagian Perkhidmatan Farmasi, Kementerian Kesihatan Malaysia (BPF KKM). Sebagai pihak berkuasa berwibawa (competent authority) kawalan substan di negara ini, BPF KKM telah dilantik sebagai agensi peneraju bagi menjalankan inisiatif SPIKES ini.

Sistem Pengurusan Integrasi Kawalan Efektif Substan (SPIKES) telah dilancarkan di Dewan Anggerik, Biro Pengawalan Farmaseutikal Kebangsaan KKM pada 23 Februari 2012.

SPIKES is a system that is used in the management and control of substances. It was developed as an outcome of the Drug Supply Suppression sub-initiative of the National Key Results Area (NKRA) Crime Lab under the Government Transformation Programme (GTP). SPIKES integrates control of substances (narcotics, psychotropic substances and precursor chemicals) and facilitates substance information sharing among other relevant enforcement agencies such as the National Anti Drug Agency (NADA), Narcotics Crime Investigation Department, Royal Malaysian Police (RMP), Preventive Division (Narcotics), Royal Malaysian Customs (RMC), Narcotics Section, Forensics Divison, Chemistry Department of Malaysia (CDM) and Pharmacy Enforcement, Pharmaceutical Services Division, Ministry of Health (MOH). PSD MOH as the nation’s competent authority for the control of substances has been appointed as the lead agency to conduct this collaboration.

SPIKES had been officially launched on 23rd February 2012 at the Anggerik Hall, National Pharmaceutical Control Bureau of Health.

Page 32: program farmasi / pharmacy programme

31PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

27 | L a p o r a n T a h u n a n 2 0 1 2

information sharing among other relevant enforcement agencies such as the National Anti Drug

Agency (NADA), Narcotics Crime Investigation Department, Royal Malaysian Police (RMP),

Preventive Division (Narcotics), Royal Malaysian Customs (RMC), Narcotics Section, Forensics

Divison, Chemistry Department of Malaysia (CDM) and Pharmacy Enforcement, Pharmaceutical

Services Division, Ministry of Health (MOH). PSD MOH as the nation’s competent authority for the

control of substances has been appointed as the lead agency to conduct this collaboration.

SPIKES had been officially launched on 23rd

October 2012 at the Anggerik Hall, National

Pharmaceutical Control Bureau of Health.

Rajah 11 : Upacara Majlis Pelancaran SPIKES

Figure 11 : Official Launching of SPIKES

28 | L a p o r a n T a h u n a n 2 0 1 2

Rajah 12 : Agensi-agensi lain terlibat dalam SPIKES

Figure 12 : Stakeholders in SPIKES

9. Tadbir Urus Baik Ubat

Good Governance for Medicines (GGM)

Dua garis panduan Good Governance of Medicines (GGM) ini telah dikemaskini dan diterbitkan pada

November 2012, iaitu Garis panduan Pemberian dan Penerimaan Hadiah untuk Anggota Farmasi,

KKM dan Garis panduan untuk Anggota Farmasi KKM Berurusan dengan Wakil Syarikat

Farmaseutikal dan Pembekal.

Unit GGM telah menerima penajaan daripada WHO Representative Office for Brunei Darussalam,

Malaysia dan Singapore sebanyak RM64,554 bagi tujuan menerbitkan garis panduan GGM dan

membangunkan modul latihan Training of Trainers (TOT) Good Governance for Medicines (GGM).

Beberapa bengkel penyediaan modul latihan TOT GGM telah diadakan seperti berikut:

• 8-9hb Mac 2012

• 2-3 April 2012

• 4-5 Jun 2012

• 5-7 November 2012 (tajaan WHO)

• 4-5 Disember 2012 (tajaan WHO)

Page 33: program farmasi / pharmacy programme

32 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

9. Tadbir Urus Baik Ubat Good Governance for Medicines (GGM)

Dua garis panduan Good Governance of Medicines (GGM) ini telah dikemaskini dan diterbitkan pada November 2012, iaitu Garis panduan Pemberian dan Penerimaan Hadiah untuk Anggota Farmasi, KKM dan Garis panduan untuk Anggota Farmasi KKM Berurusan dengan Wakil Syarikat Farmaseutikal dan Pembekal.

Unit GGM telah menerima penajaan daripada WHO Representative Office for Brunei Darussalam, Malaysia dan Singapore sebanyak RM64,554.00 bagi tujuan menerbitkan garis panduan GGM dan membangunkan modul latihan Training of Trainers (TOT) Good Governance for Medicines (GGM).

Beberapa bengkel penyediaan modul latihan TOT GGM telah diadakan seperti berikut:

• 8-9 Mac 2012• 2-3 April 2012• 4-5 Jun 2012• 5-7 November 2012 (tajaan WHO)• 4-5 Disember 2012 (tajaan WHO)

Two GGM guidelines were revised and published in November 2012. They are the Guidelines on Giving and Receiving Gifts for Civil Servants under the Pharmacy Program, Ministry of Health Malaysia and Guidelines for Pharmacy Personnel in Dealing with Pharmaceutical Company Representatives and Suppliers.

The GGM unit received co-sponsorship from the WHO Representative Office for Brunei Darussalam, Malaysia and Singapore for the GGM TOT workshops and the publication of the GGM guidelines. The fund awarded was RM64, 554.00. Several workshops to develop the GGM TOT module were conducted on these respective dates:

• 8th – 9th March 2012• 2nd – 3rd April 2012• 4th -5th June 2012• 5th – 7th November 2012 (sponsored by WHO)• 4th – 5th December 2012 (sponsored by WHO)

Page 34: program farmasi / pharmacy programme

33PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

29 | L a p o r a n T a h u n a n 2 0 1 2

Two GGM guidelines were revised and published in November 2012. They are the Guidelines on

Giving and Receiving Gifts for Civil Servants under the Pharmacy Program, Ministry of Health

Malaysia and Guidelines for Pharmacy Personnel in Dealing with Pharmaceutical Company

Representatives and Suppliers.

The GGM unit received co-sponsorship from the WHO Representative Office for Brunei Darussalam,

Malaysia and Singapore for the GGM TOT workshops and the publication of the GGM guidelines. The

fund awarded was RM64, 554.00. Several workshops to develop the GGM TOT module were

conducted on these respective dates:

• 8th – 9

th March 2012

• 2nd

– 3rd

April 2012

• 4th -5

th June 2012

• 5th – 7

th November 2012 (sponsored by WHO)

• 4th – 5

th December 2012 (sponsored by WHO)

Jadual 14: Pencapaian GGM Tahun 2012

Table 14: Achievements of GGM in 2012

Bil.

No.

Aktiviti

Activities

Output

Outputs

Pencapaian

Achievements

1.

Penyediaan Modul Latihan Training of Trainers

(TOT) GGM

Development of GGM Training of Trainers (TOT)

Module

Modul TOT GGM

The GGM TOT Module

Akan dimurnikan dan

dilancarkan pada tahun

2013.

To be endorsed and

implemented in 2013.

2. Penyemakan semula dua garis panduan GGM.

Revision of two (2) GGM guidelines

Penerbitan dua garis panduan

GGM edisi kedua.

Publication of the 2nd

edition of

two GGM guidelines.

Garis panduan GGM

diedarkan dan digunapakai

di seluruh negara.

Distribution and

implementation of the new

GGM guidelines nationwide

29 | L a p o r a n T a h u n a n 2 0 1 2

Two GGM guidelines were revised and published in November 2012. They are the Guidelines on

Giving and Receiving Gifts for Civil Servants under the Pharmacy Program, Ministry of Health

Malaysia and Guidelines for Pharmacy Personnel in Dealing with Pharmaceutical Company

Representatives and Suppliers.

The GGM unit received co-sponsorship from the WHO Representative Office for Brunei Darussalam,

Malaysia and Singapore for the GGM TOT workshops and the publication of the GGM guidelines. The

fund awarded was RM64, 554.00. Several workshops to develop the GGM TOT module were

conducted on these respective dates:

• 8th – 9

th March 2012

• 2nd

– 3rd

April 2012

• 4th -5

th June 2012

• 5th – 7

th November 2012 (sponsored by WHO)

• 4th – 5

th December 2012 (sponsored by WHO)

Jadual 14: Pencapaian GGM Tahun 2012

Table 14: Achievements of GGM in 2012

Bil.

No.

Aktiviti

Activities

Output

Outputs

Pencapaian

Achievements

1.

Penyediaan Modul Latihan Training of Trainers

(TOT) GGM

Development of GGM Training of Trainers (TOT)

Module

Modul TOT GGM

The GGM TOT Module

Akan dimurnikan dan

dilancarkan pada tahun

2013.

To be endorsed and

implemented in 2013.

2. Penyemakan semula dua garis panduan GGM.

Revision of two (2) GGM guidelines

Penerbitan dua garis panduan

GGM edisi kedua.

Publication of the 2nd

edition of

two GGM guidelines.

Garis panduan GGM

diedarkan dan digunapakai

di seluruh negara.

Distribution and

implementation of the new

GGM guidelines nationwide

Page 35: program farmasi / pharmacy programme
Page 36: program farmasi / pharmacy programme

BIRO PENGAWALAN FARMASEUTIKAL KEBANGSAAN (BPFK)

NATIONAL PHARMACEUTICAL CONTROL BUREAU (NPCB)

Page 37: program farmasi / pharmacy programme

36 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

BIRO PENGAWALAN FARMASEUTIKAL KEBANGSAAN (BPFK)NATIONAL PHARMACEUTICAL CONTROL BUREAU (NPCB)

1. Pensijilan 5S 5S Certification

Amalan 5S yang berasal dari negara Jepun kini telah menjadi praktis di Malaysia. Amalan ini memberi penekanan kepada penjagaan persekitaran tempat kerja yang sistematik bagi meningkatkan produktiviti. Kerajaan Malaysia menyokong sepenuhnya amalan ini dalam usaha untuk meningkatkan kecekapan perkhidmatan awam.

Selaras dengan itu, Biro Pengawalan Farmaseutikal Kebangsaan (BPFK) telah melancarkan kempen 5S pada bulan Julai 2010. BPFK telah melalui beberapa siri audit dalaman serta audit luaran dan berjaya mendapat markah purata sebanyak 96.23% pada audit terakhir. Dengan itu, BPFK dianugerahkan pensijlan 5S dari Unit Pemodenan Tadbiran & Perancangan Pengurusan Malaysia (MAMPU) pada 17 Disember 2012 sehingga ke pensijilan semula selepas dua tahun dari tarikh tersebut.

The 5S practice, which originated from Japan, is now being adapted in the country. This practice emphasizes on maintaining a systematic work environment in order to increase productivity. The Malaysian government fully supports this practice in the effort to improve efficiency of the public service.

In line with this, the National Pharmaceutical Control Bureau (NPCB) launched the 5S campaign back in July 2010. The NPCB went through a series of internal and external audits and scored an average of 96.23% during the final audit. NPCB was then awarded the 5S certification from the Malaysia Administrative Modernisation & Management Planning Unit (MAMPU) on 17 December 2012. The certificate has been issued with effect from 17 December 2012 to 17 December 2014.

2. Mesyuarat Teknikal Pertama Pembangunan dan Penyelarasan Standard Farmaseutikal dan Vaksin bagi Negara-negara Pertubuhan Islam (OIC)

1st Technical Meeting on Development and Harmonisation of Standards on Pharmaceuticals and Vaccines (DHSPV) among OIC Member States

Mesyuarat Teknikal Pertama Pembangunan dan Penyelarasan Standard Farmaseutikal dan Vaksin bagi Negara-negara Pertubuhan Islam (OIC-DHSPV) telah diadakan pada 1 – 2 Oktober 2012 di Pusat Perdagangan Dunia Putra, Kuala Lumpur. Penganjuran mesyuarat ini adalah hasil usaha sama di antara Kementerian Sains, Teknologi dan Inovasi (MOSTI) dan Kementerian Kesihatan Malaysia (KKM) dengan kerjasama daripada Sektretariat OIC.

Mesyuarat Teknikal ini telah dihadiri oleh wakil negara-negara OIC seperti Brunei Darussalam, Gambia, Indonesia, Malaysia and Saudi Arabia, di samping wakil-wakil dari badan-badan antarabangsa iaitu World Health Organization (WHO), Statistical, Economic and Social Research and Training Centre for Islamic Countries (SESRIC) dan Islamic Development Bank (IDB).

Mesyuarat ini telah diadakan sebagai salah satu inisiatif negara-negara anggota OIC ke arah pengeluaran farmaseutikal dan vaksin sendiri bagi memastikan bekalan farmaseutikal dan vaksin di negara-negara anggota OIC adalah berkualiti tinggi, selamat dan berkesan dengan harga yang berpatutan.

Page 38: program farmasi / pharmacy programme

37PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

Hasil daripada mesyuarat tersebut, beberapa perkara telah dipersetujui, antaranya termasuk Terms of Reference (ToR) and Struktur Jawatankuasa Teknikal OIC-DHSPV. Mesyuarat Teknikal ke-2 dicadang untuk diadakan pada tahun 2013.

The 1st Techinical Meeting on Development and Harmonisation of Standards on Pharmaceuticals and Vaccines (DHSPV) among OIC Member States was held at Putra World Trade Centre, Kuala Lumpur on 1-2 October 2012. The organization of this meeting is a joint effort between the Ministry of Science, Technology and Innovation (MOSTI) and Ministry of Health Malaysia (MOH) in collaboration with the OIC General Secretariat.

The meeting was attended by representatives from the OIC Member States i.e. Brunei Darussalam, Gambia, Indonesia, Malaysia and Saudi Arabia, as well as international bodies i.e. World Health Organization (WHO), Statistical, Economic and Social Research and Training Centre for Islamic Countries (SESRIC) and Islamic Development Bank (IDB).

The meeting was held as an initiative of the OIC Member States towards production and self-reliance of pharmaceuticals and vaccines to ensure reliable supply of good quality, safe, effective and affordable medicines and vaccines.

The meeting deliberated on the Terms of Reference (ToR) and the structure of the OIC-DHSPV Technical Committee. The 2nd Technical Meeting will be conducted in 2013.

32 | L a p o r a n T a h u n a n 2 0 1 2

The meeting deliberated on the Terms of Reference (ToR) and the structure of the OIC-DHSPV

Technical Committee. The 2nd

Technical Meeting will be conducted in 2013.

Rajah 13 : Mesyuarat Teknikal Pertama Pembangunan dan Penyelarasan Standard Farmaseutikal

dan Vaksin bagi Negara-negara Pertubuhan Islam

Figure 13 : 1st Technical Meeting on Development and Harmonisation of Standards on

Pharmaceuticals and Vaccines (DHSPV) among OIC Member States

3. Mesyuarat Teknikal Dua Hala bersama Badan Regulatori Luar

Bilateral Meeting with Other Regulatory Agencies

(a) BPFK dan Badan Pengawas Obat dan Makanan (BPOM), Republik

Indonesia

(a) NPCB and National Agency of Drug and Food Control (NA-DFC), Republic of Indonesia

Mesyuarat Teknikal Dua Hala antara BPFK dan BPOM telah diadakan pada 11 Jun 2012 dalam

usaha mempertingkatkan hubungan dan kerjasama dalam bidang regulatori farmaseutikal di

antara Malaysia dan Indonesia.

Page 39: program farmasi / pharmacy programme

38 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

3. Mesyuarat Teknikal Dua Hala bersama Badan Regulatori Luar Bilateral Meeting with Other Regulatory Agencies

(a) BPFK dan Badan Pengawas Obat dan Makanan (BPOM), Republik Indonesia

(a) NPCB and National Agency of Drug and Food Control (NA-DFC), Republic of Indonesia

Mesyuarat Teknikal Dua Hala antara BPFK dan BPOM telah diadakan pada 11 Jun 2012 dalam usaha mempertingkatkan hubungan dan kerjasama dalam bidang regulatori farmaseutikal di antara Malaysia dan Indonesia.

Mesyuarat ini telah berlangsung di Boulevard Hotel, Mid Valley, Kuala Lumpur dan melibatkan seramai 21 orang pegawai (dihadiri oleh lima orang pegawai regulatori dari BPOM, 14 orang pegawai dari BPFK serta dua orang wakil dari Bahagian Dasar & Hubungan Antarabangsa, Kementerian Kesihatan Malaysia). Mesyuarat turut dihadiri oleh seorang wakil dari Kedutaan Republik Indonesia sebagai pemerhati.

The Bilateral Meeting between NPCB and NA-DFC was conducted on 11 June 2012 as an initiative to improve the working relationship between Malaysia and Indonesia in the pharmaceutical regulatory field.

The meeting was held at Boulevard Hotel, Mid Valley, Kuala Lumpur and was attended by 21 officers (5 officers from NA-DFC, 14 officers from NPCB and 2 representatives from the Policy and International Relations Division, Ministry of Health, Malaysia). A representative from the Embassy of The Republic of Indonesian was also present as an observer.

33 | L a p o r a n T a h u n a n 2 0 1 2

Mesyuarat ini telah berlangsung di Boulevard Hotel, Mid Valley, Kuala Lumpur dan melibatkan

seramai 21 orang pegawai (dihadiri oleh lima orang pegawai regulatori dari BPOM, 14 orang

pegawai dari BPFK serta dua orang wakil dari Bahagian Dasar & Hubungan Antarabangsa,

Kementerian Kesihatan Malaysia). Mesyuarat turut dihadiri oleh seorang wakil dari Kedutaan

Republik Indonesia sebagai pemerhati.

The Bilateral Meeting between NPCB and NA-DFC was conducted on 11 June 2012 as an

initiative to improve the working relationship between Malaysia and Indonesia in the

pharmaceutical regulatory field.

The meeting was held at Boulevard Hotel, Mid Valley, Kuala Lumpur and was attended by 21

officers (5 officers from NA-DFC, 14 officers from NPCB and 2 representatives from the Policy

and International Relations Division, Ministry of Health, Malaysia). A representative from the

Embassy of The Republic of Indonesian was also present as an observer.

Rajah 14: Mesyuarat Teknikal Dua Hala BPFK dan BPOM, Republik Indonesia

Figure 14 : Technical Bilateral Meeting between NPCB & NA-DFC

Page 40: program farmasi / pharmacy programme

39PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

(b) BPFK dan Food and Drug Administration of Thailand (Thai FDA)

(b) NPCB and Food and Drug Administration of Thailand (Thai FDA)

Mesyuarat Teknikal Dua Hala di antara BPFK dan Thai FDA telah diadakan pada 2 Julai 2012 di Siam City Hotel, Bangkok, Thailand. Mesyuarat telah dihadiri oleh YBhg. Dato’ Eisah A. Rahman, Pengarah Kanan Perkhidmatan Farmasi, Kementerian Kesihatan Malaysia dan 4 orang pegawai BPFK serta 9 orang pegawai dari Thai FDA.

Mesyuarat tersebut telah membincangkan bidang kerjasama yang boleh dijalinkan di antara kedua-dua negara termasuk perkongsian maklumat berkenaan kawalan regulatori produk farmaseutikal dan program pemantauan produk di pasaran, mengadakan jaringan dan kerjasama dalam menangani masalah kekurangan ubat yang sangat diperlukan serta ubat ‘orphan’ terutama semasa krisis, kecemasan atau malapetaka serta pertukaran pengalaman berkaitan permohonan dan penghantaran maklumat atas talian.

The Bilateral Meeting between NPCB and Thai FDA was held at Siam City Hotel, Bangkok, Thailand on 2 July 2012. The meeting was attended by YBhg. Dato’ Eisah A. Rahman, Senior Director of Pharmaceutical Services, Ministry of Health Malaysia along with 4 NPCB officers and 9 officers from Thai FDA.

The meeting discussed issues in the field of cooperation between the two countries including sharing of information regarding regulatory control of pharmaceutical products and market surveillance of products, network formation and cooperation in matters pertaining to shortage of medicine supply especially orphan drugs during crisis, emergencies and natural disasters, and exchange of experiences related to online application and delivery of information.

(c) BPFK dan Health Sciences Authority (HSA), Singapura

(c) NPCB and Health Sciences Authority (HSA), Singapore

Mesyuarat Teknikal Dua Hala antara BPFK dan HSA telah diadakan dengan jayanya pada 9 April 2012 di Gardens Hotel & Residences, Kuala Lumpur. Mesyuarat ini telah dipengerusikan bersama oleh YBhg. Dato’ Eisah A. Rahman, Pengarah Kanan Perkhidmatan Farmasi, Kementerian Kesihatan Malaysia dan Prof. John Lim, Ketua Pegawai Eksekutif, Health Sciences Authority, Singapura. Mesyuarat ini telah dihadiri oleh 31 orang pegawai dari kedua-dua buah negara (21 delegasi Malaysia dan 10 delegasi dari HSA, Singapura). Antara perkara yang telah dibincangkan adalah pemeriksaan bersama dari aspek Amalan Perkilangan Baik, pemeriksaan tapak BA/BE, penilaian bersama bagi “dossiers”, isu penguatkuasaan serta latihan antara agensi.

Hasil daripada mesyuarat ini, satu program kerjasama dalam bidang regulatori farmaseutikal di antara BPFK dengan HSA telah dibangunkan dan dipersetujui oleh kedua-dua pihak. Mesyuarat juga bersetuju agar mesyuarat ini diadakan setiap tahun dan HSA akan menjadi tuan rumah bagi tahun 2013.

Page 41: program farmasi / pharmacy programme

40 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

The Bilateral Meeting between NPCB and HSA was held successfully on 9 April 2012 at the Gardens Hotel & Residences, Kuala Lumpur. This meeting was chaired by YBhg. Dato’ Eisah A. Rahman, Senior Director of Pharmaceutical Services, Ministry of Health, Malaysia and Prof. John Lim, Chief Executive Officer of the Health Sciences Authority, Singapore. The meeting was attended by 31 officers from both countries (21 delegates from Malaysia and 10 delegates from HSA, Singapore). Among the issues discussed were Good Manufacturing Practice (GMP) joint inspection, inspection of BA/BE sites, joint evaluation of dossiers, enforcement issues and training for both agencies.

At the end of the meeting, a programme of cooperation in the field of pharmaceutical regulatory between NPCB and HSA was developed and agreed upon by both parties. Both parties also agreed that the bilateral meeting is to be conducted every year and HSA will be the host for the year 2013.

35 | L a p o r a n T a h u n a n 2 0 1 2

Hasil daripada mesyuarat ini, satu program kerjasama dalam bidang regulatori farmaseutikal di antara

BPFK dengan HSA telah dibangunkan dan dipersetujui oleh kedua-dua pihak. Mesyuarat juga

bersetuju agar mesyuarat ini diadakan setiap tahun dan HSA akan menjadi tuan rumah bagi tahun

2013.

The Bilateral Meeting between NPCB and HSA was held successfully on 9 April 2012 at the Gardens

Hotel & Residences, Kuala Lumpur. This meeting was chaired by YBhg. Dato’ Eisah A. Rahman,

Senior Director of Pharmaceutical Services, Ministry of Health, Malaysia and Prof. John Lim, Chief

Executive Officer of the Health Sciences Authority, Singapore. The meeting was attended by 31

officers from both countries (21 delegates from Malaysia and 10 delegates from HSA, Singapore).

Among the issues discussed were Good Manufacturing Practice (GMP) joint inspection, inspection of

BA/BE sites, joint evaluation of dossiers, enforcement issues and training for both agencies.

At the end of the meeting, a programme of cooperation in the field of pharmaceutical regulatory

between NPCB and HSA was developed and agreed upon by both parties. Both parties also agreed

that the bilateral meeting is to be conducted every year and HSA will be the host for the year 2013.

Rajah 15 : Mesyuarat Teknikal Dua Hala BPFK dan HSA, Singapura

Figure 15 : Bilateral Meeting between NPCB & HSA

.

Page 42: program farmasi / pharmacy programme

41PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

4. Memorandum Persefahaman (MoU) antara Kementerian Kesihatan Malaysia dan Health Sciences Authority, Singapura 4. Memorandum of Understanding (MoU) between Ministry of Health, Malaysia and Health Sciences Authority (HSA), Singapore

Memorandum Persefahaman (MoU) antara Kementerian Kesihatan Malaysia (KKM) dan Health Sciences Authority (HSA), Singapura telah berjaya ditandatangani pada 28 Mac 2012 di Singapura. Majlis ini telah disaksikan oleh Menteri Kesihatan dari kedua-dua negara. Ia merupakan salah satu peristiwa penting bagi Biro Pengawalan Farmaseutikal Kebangsaan secara khususnya dan Bahagian Perkhidmatan Farmasi secara amnya kerana ia merupakan MoU pertama yang berjaya ditandatangani oleh Malaysia dalam bidang regulatori farmaseutikal.

Antara bidang kerjasama yang telah dipersetujui adalah kerjasama dalam bidang regulatori farmaseutikal, perkongsian maklumat berkaitan aktiviti penguatkuasaan, surveilans, farmakovigilans, pengujian sampel, pemeriksaan Amalan Perkilangan Baik dan kajian klinikal serta kolaborasi dalam semua bidang yang mempunyai impak ke atas kesihatan awam yang berkaitan dengan produk farmaseutikal.

A Memorandum of Understanding (MoU) between the Ministry of Health, Malaysia and Health Sciences Authority (HSA), Singapore was successfully signed on 28 March 2012 in Singapore. The memorable event was witnessed by the Minister of Health of both countries. This was a very significant event particularly for the National Pharmaceutical Control Bureau and the Pharmaceutical Services Division as it is the first MoU signed by Malaysia in the field of pharmaceutical regulatory.

Among the field of cooperation which has been agreed upon is the pharmaceutical regulatory field, information sharing in regards to enforcement activities, surveillance, pharmacovigilance, sample testing, Good Manufacturing Practice inspections and clinical studies along with collaboration in all fields relating to pharmaceutical products which has an impact on the health of the public.

Page 43: program farmasi / pharmacy programme
Page 44: program farmasi / pharmacy programme

HALATUJU

WAY FORWARD

Page 45: program farmasi / pharmacy programme

44 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

AMALAN DAN PERKEMBANGAN FARMASI

Aktiviti-aktiviti yang dijalankan oleh Amalan dan Perkembangan Farmasi tertumpu kepada memberi perkhidmatan penjagaan farmasi yang terbaik bersesuaian dengan keperluan pada masa kini. Bagi menyediakan sistem penjagaan kesihatan yang seragam dan berkualiti, garis panduan dan modul latihan akan dikemaskini. Di samping itu, perkhidmatan Home Medication Review akan diperluaskan supaya kesinambungan penjagaan dari fasiliti kesihatan ke rumah pesakit dapat diteruskan.

Strategi yang akan dijalankan bagi memperkukuhkan penggunaan ubat secara berkualiti ialah melalui perluasan aktiviti Duta Kenali Ubat Anda ke peringkat negeri. Aktiviti-aktiviti ini memberi penghakupayaan masyarakat terhadap penggunaan ubat secara lebih bertanggungjawab dan dengan itu akan dapat membantu meningkatkan penggunaan ubat secara berkesan dan selamat.

Bahagian ini juga menekankan kewujudan ekosistem yang menyokong pertumbuhan penyelidikan klinikal melalui meningkatkan daya saing antara penyelidik serta penyebaran dan penggunaan bukti penyelidikan untuk meningkatkan mutu perkhidmatan.

Berdasarkan pelan strategik Dasar Ubat Nasional, bahagian ini akan menumpukan aktiviti-aktiviti ke arah memastikan ketersediaan ubat-ubat yang selamat, berkesan, berkualiti dan kos efektif secara berterusan serta meningkatkan akses kepada maklumat harga ubat–ubatan yang mampu diperolehi oleh rakyat. Tahun 2013 akan melibatkan perbincangan dengan pihak yang berkepentingan untuk mencapai objektif ini.

Bagi memastikan ahli farmasi yang kompeten dan memenuhi keperluan di

PHARMACY PRACTICE AND DEVELOPMENT

Activities carried out by the Pharmacy Practice and Development is focused on giving the best pharmaceutical care services in line with current needs. Training modules and guidelines will be updated to standardise and enhance the quality of pharmaceutical care. In addition, Home Medication Review services will be expanded to enable a continous care from health facilities to patients’ homes.

The strategy to strengthen quality use of medicines is by extending the Know Your Medicines Ambassadors activities to states. These activities empowers the public towards responsible use of medicines which in turn helps to enhance safe and effective use of medicines.

This division also stresses on having an ecosystem which supports the growth of clinical research through increasing researcher competitiveness as well as dissemination and use of research evidences to improve services. Based on the strategic plan of the National Medicines Policy, this division will focus on activities to ensure continuous supply of safe, effective, cost-effective and quality medicines as well as improve access to information on prices of medicines that is affordable by Malaysians. The year 2013 will involve discussions with stakeholders to achieve this objective. To ensure pharmacists are competent and meet the needs of the pharmaceutical industry, several measures are being proposed which is to strengthen monitoring of pharmacy programs in accredited higher education institutions locally and abroad as well as the liberalisation of provisional registered pharmacists’ training at gazetted private facilities.

HALATUJU WAY FORWARD

Page 46: program farmasi / pharmacy programme

45PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

industri farmaseutikal, beberapa langkah telah dicadangkan seperti memantapkan pemantauan program farmasi di institusi pengajian tinggi tempatan dan luar negara yang memenuhi akreditasi yang ditetapkan serta liberalisasi latihan ahli farmasi pendaftaran bersyarat di fasiliti swasta yang diwartakan.

UBAT-UBATAN SUBSTANDARD DAN PALSU ATAU LANCUNG (SSFFC)

Bahagian Penguatkuasaan Farmasi akan terus berusaha untuk memastikan semua produk farmaseutikal, tradisional, suplemen kesihatan dan kosmetik dalam pasaran adalah sah dari segi pendaftaran dan notifikasinya. Masalah ubat-ubatan substandard dan palsu atau lancung atau yang diistilahkan oleh WHO sebagai SSFFC, memberi kesan kepada industri farmaseutikal negara. Peningkatan kerjasama antara semua agensi dalam mencari pendekatan terbaik untuk bertindak balas kepada gejala produk SSFFC dan mencegah daripada mencerobohi rantaian pengedaran serta mengelakkan penyusupan ke pasaran negara kita adalah penting demi untuk memastikan pembuatan, pengedaran dan penjualan produk SSFFC dapat dihalang sebelum ianya menjadi masalah yang membahayakan kesihatan masyarakat pengguna dan memberi kesan ke atas kredibiliti perkhidmatan kesihatan.

RANG UNDANG-UNDANG FARMASI (RUUF)

Bahagian Penguatkuasa Farmasi akan menyelaras penyediaan peraturan, arahan dan garis panduan di bawah Rang Undang-Undang Farmasi (RUUF) untuk memastikan akta ini dapat diimplementasikan sebaik sahaja ianya diluluskan di parlimen.

SUBSTANDARD/ SPURIOUS/ FALSELY-LABELLED/ FALSIFIED/ COUNTERFEIT MEDICINES (SSFFC)

Pharmacy Enforcement Division will continue to ensure that pharmaceutical, traditional, health supplements and cosmetic products that are available in the market are genuine in terms of registration and notification. Problem of substandard/ spurious/ falsely-labeled/ falsified/ counterfeit or named by the WHO as SSFFC, gives an impact on the country’s pharmaceutical industry. Increased cooperation between all agencies in finding the best approach for responding to the phenomenon of SSFFC and preventing it’s encroachment into supply chain and market penetration in our country is important in order to ensure that the manufacture, supply and sale of SSFFC products can be curbed before it becomes a problem that endanger the public health and gives an impact on the credibility of health services.

NEW PHARMACY BILL

Enforcement Division will coordinate the preparation of regulations, directives and guidelines under the New Pharmacy Bill to ensure that this act can be implemented once it is approved in parliament.

Page 47: program farmasi / pharmacy programme

46 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

BIRO PENGAWALAN FARMASEUTIKAL KEBANGSAAN

Garis Panduan Pendaftaran Produk (DRGD), dokumen rujukan bagi proses pendaftaran produk, akan sentiasa dikemaskini dengan maklumat berkaitan kawalan kualiti, pemeriksaan premis dan perlesenan. Mulai tahun 2013, pengkelasan bagi produk-produk yang berada di bawah kategori interfasa Makanan-Ubat akan dilaksanakan oleh BPFK.

Selain itu, BPFK akan menjalankan pemeriksaan pusat kajian Bio-equivalance (BE) luar negara. Produk berdaftar generik yang sedia ada dalam pasaran telah diberikan sehingga 1 Januari 2014 untuk mematuhi keperluan BE.

Sebagai langkah menambahbaik perkhidmatan yang diberikan, kertas cadangan untuk implementasi Malaysian Variation Guideline (MVG) akan dibentangkan pada tahun 2013. Selain itu, satu latihan kepada pihak industri farmaseutikal mengenai MVG akan diadakan.

BPFK akan terus berusaha menerokai bidang ujian analitikal bahan farmaseutikal aktif, vaksin dan produk bioteknologi. Metodologi untuk pengesanan sebatian penanda dalam spesies tumbuhan yang digunakan dalam produk perubatan semulajadi akan dibangunkan selain bekerjasama dengan institusi kerajaan lain dalam bidang penyelidikan bahan toksik dan sebatian penanda negatif dalam bahan mentah dan produk perubatan semula jadi.

BPFK yakin untuk menjadi ahli bukan OECD yang patuh kepada sistem Mutual Acceptance of Data (MAD), di mana Malaysia akan menjadi salah satu hub kajian bukan klinikal di Asia Tenggara.

BPFK berhasrat untuk mengadakan lebih banyak kerjasama dengan agensi-agensi regulatori luar negara

NATIONAL PHARMACEUTICAL CONTROL BUREAU

The Drug Registration Guidance Document (DRGD), the reference guide for product registration, will be regularly updated with information pertaining to quality control, inspection and licensing. Starting from 2013, the classification of products under the Food-Drug interphase category will be done by NPCB.

Besides that, NPCB will be conducting inspection of overseas Bio-equivalence (BE) centres. Existing registered generic products in the market have been given until 1st January 2014 to comply with the BE requirements.

In order to improve the services provided, the proposal for implementation of the Malaysian Variation Guideline (MVG) will be presented in 2013. Besides that, a training course on the MVG for the pharmaceutical industry will be held.

NPCB will venture into analytical testing of Active Pharmaceutical Ingredients (APIs), vaccines and biotechnology products. Methodologies for detection of marker compound in plant species used in natural medicinal products will be developed as well as collaboration with other government institutions in research of toxic substances and negative marker compound in natural raw materials and products.

NPCB is positive in being a non-OECD member adhering to the Mutual Acceptance of Data (MAD) System, where Malaysia will be one of the non-clinical studies hubs in Southeast Asia.

NPCB looks forward to having more collaboration with other international regulatory agencies through Technical Bilateral Meetings and formal Memorandum of Understanding (MoU). NPCB will take part in the development of ASEAN Non-Pharmacopeial Analytical Method under ASEAN Working Group on Pharmaceutical

Page 48: program farmasi / pharmacy programme

47PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

melalui mesyuarat teknikal dua-hala dan Memorandum of Understanding (MoU). BPFK akan mengambil bahagian dalam pembangunan ‘ASEAN Non-Pharmacopoeia Analytical Method under ASEAN Working Group on Pharmaceutical Development (AWGPD)’ yang memberi tumpuan kepada pengesanan bahan campurpalsu farmaseutikal di dalam produk semulajadi

Development (AWGPD) focusing on the detection of pharmaceutical adulterants in traditional medicines.

KESIMPULAN SUMMARY

Empat aktiviti utama di bawah Program Farmasi seperti Dasar dan Pengurusan Farmasi, Amalan dan Perkembangan Farmasi, Penguatkuasaan Farmasi dan Biro Pengawalan Farmaseutikal Kebangsaan telah mencapai kejayaan dalam pelaksanaannya pada tahun 2012. Aktiviti-aktiviti sedia ada dan perkhidmatan farmasi yang disediakan akan diperkukuhkan bagi memastikan hanya produk farmaseutikal dan kesihatan yang berkualiti, selamat dan berkesan disediakan dan mampu milik kepada orang ramai dan digunakan secara berkualiti.

The four main activities such as Policy and Pharmacy Management, Pharmacy Practice and Development, Pharmacy Enforcement and National Pharmaceutical Control Bureau (NPCB) under the Pharmacy Programme were successfully carried out in year 2012. Existing activities and pharmacy services provided will be strengthened to ensure only quality, safe and efficacious pharmaceutical and health products are available and affordable to the public and use of medicines is judicious.

Page 49: program farmasi / pharmacy programme

48 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

JAWATANKUASA EDITORIAL EDITORIAL COMMITTEE

Penasihat | Advisor : Dato’ Eisah binti A. RahmanPengerusi | Chairperson : Dr. Nour Hanah binti OthmanAhli | Members : Puan Wan Mohaina binti Wan Mohammad : Puan Rohaida binti Zakaria : Cik Siti Hufaidah binti Suhimi : En. Kamaruddin bin Ahmad : Puan Kon Ee Wen : Cik Syuhadah Mohamed Hassan : En. Muhammad Syafiq bin Saleh : En. Soon Thien Loong : Cik Yap Fei Ting : En. Muhammad Mawardi bin Zakaria

Jawatankuasa Editorial ingin merakamkan setinggi-tinggi penghargaan kepada semua yang terlibat dalam memberi sumbangan dan kerjasama sama ada secara langsung atau tidak langsung dalam menjayakan penerbitan laporan tahunan Bahagian Perkhidmatan Farmasi 2012 ini.

The Editorial Committee would like to acknowledge all sections of the Pharmaceutical Services Division, Ministry of Health Malaysia for their contribution towards the production of the 2012 Annual Report.

Page 50: program farmasi / pharmacy programme

LAMPIRAN

ANNEXURE

Page 51: program farmasi / pharmacy programme

50 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

LAMPIRAN

1 | L a p o r a n T a h u n a n 2 0 1 2

STATISTIK | STATISTIC

Jadual 1: Pencapaian Perkhidmatan Farmasi Klinikal & Teknikal

Table1: Clinical & Technical Pharmacy Services Achievements

Bil.

No.

Jenis Perkhidmatan

Types of Services

Pencapaian(2012)

Achievements(2012)

1

Perkhidmatan Kaunseling

Ubat

Medication Counselling

Services

i. Bilangan pesakit menerima kaunseling

Number of Patients Counselled

Pesakit Dalam | Inpatient

Pesakit Luar | Outpatient

Discaj Wad | Ward Discharge

Pesakit Luar | Outpatient

(Klinik Kesihatan | Health Clinic)

ii. Jumlah pesakit menerima kaunseling

Total number of patients counselled

165,355

224,277

215,571

382,489

987,692

2

Perkhidmatan Farmokinetik

Klinikal

Clinical Pharmacokinetics

Services

i. Bilangan Hospital | Number of Hospitals

ii. Bilangan Kes | Number of Cases

iii. Bilangan Ubat | Number of Drugs

127

104,761

18

3

Perkhidmatan Nutrisi

Parenteral

Parenteral Nutrition

Services

i. Bilangan Hospital | Number of Hospitals

ii. Bilangan Kes | Number of Cases

iii. Bilangan Persediaan | Number of Preparations

39

11,674

96,298

4

Perkhidmatan Admikstur

Intravena

Intravenous Admixture

Services

i. Bilangan Hospital | Number of Hospitals

ii. Bilangan Persediaan | Number of Preparations

24

207,138

5

Perkhidmatan Farmasi

Onkologi

Oncology Pharmacy

Services

i. Bilangan Hospital | Number of Hospitals

ii. Bilangan Kes | Number of Cases

iii. Bilangan Persediaan| Number of Preparations

54

97,328

233,171

6

Perkhidmatan

Pendispensan Ubat Pesakit

Luar

Outpatient Drug Dispensing

Services

A. Hospital | Hospitals

i. Bilangan preskripsi diterima

Number of prescriptions received

ii. Bilangan preskripsi diintervensi

Number of Prescriptions Intervened

B. Klinik Kesihatan | Health Clinics

iii. Bilangan preskripsi diterima

Number of Prescriptions Received

iv. Bilangan Preskripsi diintervensi

Number of Prescriptions Intervened

19,101,188

18,040,774

28,438,975

20,246,619

LAMPIRAN

2 | L a p o r a n T a h u n a n 2 0 1 2

Bil.

No.

Jenis Perkhidmatan

Types of Services

Pencapaian(2012)

Achievements(2012)

C. Jumlah preskripsi diterima

Total number of Prescriptions Received

D. Jumlah preskripsi diintervensi

Total number of Prescriptions Intervened

47,540,163

38,287,393

7

Medication Therapy

Adherence Clinic

Medication Therapy

Adherence Clinic

i. Bilangan MTAC Fasiliti

Number of Facilities offering MTAC Services

ii. Bilangan Pesakit dalam perkhidmatan MTAC

Number of patients recruited into MTAC

Services

662

23,446

8 Methadone

Methadone

Fasiliti Pendispensan Methadone

Methadone Dispensing Facilities

i. Hospital | Hospitals

ii. Klinik Kesihatan | Health Clinics

49

203

9

Perkhidmatan Farmasi

Nuklear

Nuclear Pharmacy Services

i. Bilangan Hospital | Number of Hospitals

ii. Bilangan persediaan kit-based

Number of Kit-Based Preparations

iii. Bilangan persediaan 18F-FDG

Number of 18F-FDG Preparations

5

9,350

235

10 Sistem Unit Dos

Unit Dose System

i. Bilangan Hospital Negeri & HKL

Number of State Hospitals & HKL

ii. Bilangan Hospital Pakar Major

Number of Major Specialists’ Hospitals

iii. Bilangan Hospital Pakar Minor & Hospital

Bukan Pakar

Number of Minor Specialists’ & Non

Specialists’ Hospitals

13

24

37

Page 52: program farmasi / pharmacy programme

51PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012LAMPIRAN

2 | L a p o r a n T a h u n a n 2 0 1 2

Bil.

No.

Jenis Perkhidmatan

Types of Services

Pencapaian(2012)

Achievements(2012)

C. Jumlah preskripsi diterima

Total number of Prescriptions Received

D. Jumlah preskripsi diintervensi

Total number of Prescriptions Intervened

47,540,163

38,287,393

7

Medication Therapy

Adherence Clinic

Medication Therapy

Adherence Clinic

i. Bilangan MTAC Fasiliti

Number of Facilities offering MTAC Services

ii. Bilangan Pesakit dalam perkhidmatan MTAC

Number of patients recruited into MTAC

Services

662

23,446

8 Methadone

Methadone

Fasiliti Pendispensan Methadone

Methadone Dispensing Facilities

i. Hospital | Hospitals

ii. Klinik Kesihatan | Health Clinics

49

203

9

Perkhidmatan Farmasi

Nuklear

Nuclear Pharmacy Services

i. Bilangan Hospital | Number of Hospitals

ii. Bilangan persediaan kit-based

Number of Kit-Based Preparations

iii. Bilangan persediaan 18F-FDG

Number of 18F-FDG Preparations

5

9,350

235

10 Sistem Unit Dos

Unit Dose System

i. Bilangan Hospital Negeri & HKL

Number of State Hospitals & HKL

ii. Bilangan Hospital Pakar Major

Number of Major Specialists’ Hospitals

iii. Bilangan Hospital Pakar Minor & Hospital

Bukan Pakar

Number of Minor Specialists’ & Non

Specialists’ Hospitals

13

24

37

LAMPIRAN

2 | L a p o r a n T a h u n a n 2 0 1 2

Bil.

No.

Jenis Perkhidmatan

Types of Services

Pencapaian(2012)

Achievements(2012)

C. Jumlah preskripsi diterima

Total number of Prescriptions Received

D. Jumlah preskripsi diintervensi

Total number of Prescriptions Intervened

47,540,163

38,287,393

7

Medication Therapy

Adherence Clinic

Medication Therapy

Adherence Clinic

i. Bilangan MTAC Fasiliti

Number of Facilities offering MTAC Services

ii. Bilangan Pesakit dalam perkhidmatan MTAC

Number of patients recruited into MTAC

Services

662

23,446

8 Methadone

Methadone

Fasiliti Pendispensan Methadone

Methadone Dispensing Facilities

i. Hospital | Hospitals

ii. Klinik Kesihatan | Health Clinics

49

203

9

Perkhidmatan Farmasi

Nuklear

Nuclear Pharmacy Services

i. Bilangan Hospital | Number of Hospitals

ii. Bilangan persediaan kit-based

Number of Kit-Based Preparations

iii. Bilangan persediaan 18F-FDG

Number of 18F-FDG Preparations

5

9,350

235

10 Sistem Unit Dos

Unit Dose System

i. Bilangan Hospital Negeri & HKL

Number of State Hospitals & HKL

ii. Bilangan Hospital Pakar Major

Number of Major Specialists’ Hospitals

iii. Bilangan Hospital Pakar Minor & Hospital

Bukan Pakar

Number of Minor Specialists’ & Non

Specialists’ Hospitals

13

24

37

LAMPIRAN

3 | L a p o r a n T a h u n a n 2 0 1 2

Rajah 1: Nisbah Ahli Farmasi : Populasi (2005-2020)

Figure 1: Pharmacists : Population Ratio (2005-2020)

52904871

45334199

38783592

3282 29462662 2437 2249

2087 1952 1834 1731 1643

0

1000

2000

3000

4000

5000

6000

2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020

Nisbah Ahli Farmasi: PopulasiPharmacists : Population Ratio

Page 53: program farmasi / pharmacy programme

52 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

L

AM

PIR

AN

4

| L

ap

or

an

T

ah

un

an

2

01

2

Jad

ual

2:

Sen

ara

i U

niv

ers

iti d

i d

ala

m N

eg

ara

ya

ng

men

aw

ark

an

Pro

gra

m I

jazah

Farm

asi

(20

12

)

Tab

le 2

: L

ist

of

un

ivers

itie

s o

fferi

ng

Ph

arm

ac

y P

rog

ram

me c

ou

rses

(20

12)

*Fu

lly r

eco

gn

ised

by P

ha

rmac

y B

oard

Ma

lay

sia

Bil

.

No

. In

sti

tus

i |

Insti

tuti

on

P

rog

ram

| P

rog

ram

me

1.

Un

ive

rsiti S

ain

s M

ala

ysia

| U

niv

ers

ity o

f S

ain

s M

ala

ysia

S

arj

an

a M

uda

Fa

rma

si (k

ep

ujia

n)*

| B

ache

lor

of

Ph

arm

acy (

Hon

s)*

2.

Un

ive

rsiti K

eb

an

gsa

an

Mala

ysia

N

atio

na

l U

niv

ers

ity o

f M

ala

ysia

S

arj

an

a M

uda

Fa

rma

si (k

ep

ujia

n)*

|

Ba

ch

elo

r of

Pha

rmacy (

Ho

ns)*

3.

Un

ive

rsiti M

ala

ya | U

niv

ers

ity o

f M

ala

ya

S

arj

an

a M

uda

Fa

rma

si (k

ep

ujia

n)*

|

Ba

ch

elo

r of

Pha

rmacy (

Ho

ns)*

4.

Un

ive

rsiti T

ekn

olo

gi M

AR

A

Un

ive

rsity o

f T

ech

no

log

y M

AR

A

Sarj

an

a M

uda

Fa

rma

si (k

ep

ujia

n)*

| B

ache

lor

of

Ph

arm

acy (

Hon

s)*

5.

Un

ive

rsiti Is

lam

An

tara

ba

ng

sa

Ma

laysia

(U

IAM

) In

tern

atio

na

l Is

lam

ic U

niv

ers

ity M

ala

ysia

(II

UM

) S

arj

an

a M

uda

Fa

rma

si (k

ep

ujia

n)*

| B

ache

lor

of

Ph

arm

acy (

Hon

s)*

6.

Un

ive

rsiti U

CS

I | U

CS

I U

niv

ers

ity

Sarj

an

a M

ud

a F

arm

asi (k

ep

ujia

n)*

| B

ache

lor

of

Ph

arm

acy (

Hon

s)*

7.

Un

ive

rsiti P

eru

bata

n A

nta

rab

an

gsa

Ma

laysia

(IM

U)

Inte

rnatio

na

l M

ed

ical U

niv

ers

ity (

IMU

)

Sarj

an

a F

arm

asi (P

rog

ram

Be

rke

mb

ar

bers

am

a S

trath

cly

de U

niv

ers

iti,

UK

2 ½

+1

)*

Ma

ste

r of

Pha

rmacy (

twin

ing

2 ½

+ 1

with U

niv

ers

ity S

tra

thcly

de

, U

K)

*

Sarj

an

a F

arm

asi (P

rog

ram

Be

rkem

ba

r b

ers

am

a S

trath

cly

de U

niv

ers

iti,

UK

2 +

2)*

M

aste

r of

Pha

rmacy (

twin

ing

2 +

2 w

ith

Un

ivers

ity S

tra

thcly

de

, U

K)

*

Sarj

an

a M

ud

a F

arm

asi (k

ep

ujia

n)*

Ba

ch

elo

r o

f P

ha

rma

cy (

Ho

ns)*

L

AM

PIR

AN

4

| L

ap

or

an

T

ah

un

an

2

01

2

Jad

ual

2:

Sen

ara

i U

niv

ers

iti d

i d

ala

m N

eg

ara

ya

ng

men

aw

ark

an

Pro

gra

m I

jazah

Farm

asi

(20

12

)

Tab

le 2

: L

ist

of

un

ivers

itie

s o

fferi

ng

Ph

arm

ac

y P

rog

ram

me c

ou

rses

(20

12)

*Fu

lly r

eco

gn

ised

by P

ha

rmac

y B

oard

Ma

lay

sia

Bil

.

No

. In

sti

tus

i |

Insti

tuti

on

P

rog

ram

| P

rog

ram

me

1.

Un

ive

rsiti S

ain

s M

ala

ysia

| U

niv

ers

ity o

f S

ain

s M

ala

ysia

S

arj

an

a M

uda

Fa

rma

si (k

ep

ujia

n)*

| B

ache

lor

of

Ph

arm

acy (

Hon

s)*

2.

Un

ive

rsiti K

eb

an

gsa

an

Mala

ysia

N

atio

na

l U

niv

ers

ity o

f M

ala

ysia

S

arj

an

a M

uda

Fa

rma

si (k

ep

ujia

n)*

|

Ba

ch

elo

r of

Pha

rmacy (

Ho

ns)*

3.

Un

ive

rsiti M

ala

ya | U

niv

ers

ity o

f M

ala

ya

S

arj

an

a M

uda

Fa

rma

si (k

ep

ujia

n)*

|

Ba

ch

elo

r of

Pha

rmacy (

Ho

ns)*

4.

Un

ive

rsiti T

ekn

olo

gi M

AR

A

Un

ive

rsity o

f T

ech

no

log

y M

AR

A

Sarj

an

a M

uda

Fa

rma

si (k

ep

ujia

n)*

| B

ache

lor

of

Ph

arm

acy (

Hon

s)*

5.

Un

ive

rsiti Is

lam

An

tara

ba

ng

sa

Ma

laysia

(U

IAM

) In

tern

atio

na

l Is

lam

ic U

niv

ers

ity M

ala

ysia

(II

UM

) S

arj

an

a M

uda

Fa

rma

si (k

ep

ujia

n)*

| B

ache

lor

of

Ph

arm

acy (

Hon

s)*

6.

Un

ive

rsiti U

CS

I | U

CS

I U

niv

ers

ity

Sarj

an

a M

ud

a F

arm

asi (k

ep

ujia

n)*

| B

ache

lor

of

Ph

arm

acy (

Hon

s)*

7.

Un

ive

rsiti P

eru

bata

n A

nta

rab

an

gsa

Ma

laysia

(IM

U)

Inte

rnatio

na

l M

ed

ical U

niv

ers

ity (

IMU

)

Sarj

an

a F

arm

asi (P

rog

ram

Be

rke

mb

ar

bers

am

a S

trath

cly

de U

niv

ers

iti,

UK

2 ½

+1

)*

Ma

ste

r of

Pha

rmacy (

twin

ing

2 ½

+ 1

with U

niv

ers

ity S

tra

thcly

de

, U

K)

*

Sarj

an

a F

arm

asi (P

rog

ram

Be

rkem

ba

r b

ers

am

a S

trath

cly

de U

niv

ers

iti,

UK

2 +

2)*

M

aste

r of

Pha

rmacy (

twin

ing

2 +

2 w

ith

Un

ivers

ity S

tra

thcly

de

, U

K)

*

Sarj

an

a M

ud

a F

arm

asi (k

ep

ujia

n)*

Ba

ch

elo

r o

f P

ha

rma

cy (

Ho

ns)*

L

AM

PIR

AN

5

| L

ap

or

an

T

ah

un

an

2

01

2

Bil

.

No

. In

sti

tus

i |

Insti

tuti

on

P

rog

ram

| P

rog

ram

me

8.

AIM

ST

Un

ivers

iti | A

IMS

T U

niv

ers

ity

Sarj

an

a M

uda

Fa

rma

si (k

ep

ujia

n)*

| B

ache

lor

of

Ph

arm

acy (

Hon

s)*

9.

Un

ive

rsiti N

ott

ing

ha

m K

am

pu

s M

ala

ysia

(U

NM

C)

Un

ive

rsity N

ott

ing

ha

m M

ala

ysia

Ca

mp

us (

UN

MC

)

Sarj

an

a F

arm

asi*

(2+

2 s

am

a d

eng

an

pro

gra

m N

ott

ing

ha

m U

niv

ers

iti)

Ma

ste

r in

Pha

rmacy 2

+2

sim

ilar

* p

rog

ram

me

of

Un

ive

rsity N

ott

ing

ha

m,

UK

10

. K

ole

j U

niv

ers

iti S

ain

s P

eru

ba

tan

Cyb

erj

aya

(C

UC

MS

) C

ybe

rja

ya U

niv

ers

ity C

olle

ge

of

Me

dic

al S

cie

nce

s

(CU

CM

S)

S

arj

an

a M

ud

a F

arm

asi (k

ep

ujia

n)*

| B

ache

lor

of

Ph

arm

acy (

Hon

s)*

11

.

Un

ive

rsiti A

sia

Me

tro

po

lita

n (

AM

U)

(Ko

lej U

niv

ers

iti S

ain

s K

esih

ata

n M

aste

rskill

) A

sia

Metr

op

olit

an

Un

ive

rsity (

AM

U)

(Ma

ste

rskill

Un

ive

rsity C

olle

ge

of

He

alth

Scie

nce

s)

Sarj

an

a M

ud

a F

arm

asi (k

ep

ujia

n)

4+

0 d

en

ga

n L

a T

rop

e U

niv

ers

iti,

Austr

alia

B

ach

elo

r of

Ph

arm

acy (

Hon

s)

4+

0 w

ith

Univ

ers

ity L

a T

rop

e,

Au

str

alia

12

. U

niv

ers

iti M

ana

ge

me

nt

& S

cie

nce

(M

SU

)

Man

ag

em

en

t &

Scie

nce

Un

ive

rsity (

MS

U)

Sarj

an

a M

ud

a F

arm

asi (k

ep

ujia

n)*

| B

ache

lor

of

Ph

arm

acy (

Hon

s)*

13

. U

niv

ers

iti S

EG

I | S

EG

I U

niv

ers

ity

Sarj

an

a F

arm

asi (P

rog

ram

Be

rke

mb

ar

bers

am

a S

un

de

rla

nd

Un

ive

rsiti,

UK

2+

2)

Ma

ste

r of

Pha

rmacy (

2+

2 tw

inn

ing w

ith U

niv

ers

ity o

f S

und

erl

an

d,

UK

)

14

. U

niv

ers

iti M

ona

sh

Ka

mp

us M

ala

ysia

M

on

ash

Un

ive

rsity M

ala

ysia

Cam

pu

s

Sarj

an

a M

ud

a F

arm

asi (k

ep

ujia

n)

sam

a d

en

gan

pro

gra

m U

niv

ers

iti

Mo

na

sh

, A

ustr

alia

B

ach

elo

r of

Ph

arm

acy (

Hon

s)

sim

ilar

pro

gra

mm

e o

f M

on

ash

Un

ive

rsity,

Austr

alia

15

. U

niv

ers

iti M

AH

SA

| M

AH

SA

Un

ive

rsity

Sarj

an

a M

ud

a F

arm

asi (k

ep

ujia

n)

| B

ache

lor

of

Ph

arm

acy (

Hon

s)

Page 54: program farmasi / pharmacy programme

53PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

L

AM

PIR

AN

5

| L

ap

or

an

T

ah

un

an

2

01

2

Bil

.

No

. In

sti

tus

i |

Insti

tuti

on

P

rog

ram

| P

rog

ram

me

8.

AIM

ST

Un

ivers

iti | A

IMS

T U

niv

ers

ity

Sarj

an

a M

uda

Fa

rma

si (k

ep

ujia

n)*

| B

ache

lor

of

Ph

arm

acy (

Hon

s)*

9.

Un

ive

rsiti N

ott

ing

ha

m K

am

pu

s M

ala

ysia

(U

NM

C)

Un

ive

rsity N

ott

ing

ha

m M

ala

ysia

Ca

mp

us (

UN

MC

)

Sarj

an

a F

arm

asi*

(2+

2 s

am

a d

eng

an

pro

gra

m N

ott

ing

ha

m U

niv

ers

iti)

Ma

ste

r in

Pha

rmacy 2

+2

sim

ilar

* p

rog

ram

me

of

Un

ive

rsity N

ott

ing

ha

m,

UK

10

. K

ole

j U

niv

ers

iti S

ain

s P

eru

ba

tan

Cyb

erj

aya

(C

UC

MS

) C

ybe

rja

ya U

niv

ers

ity C

olle

ge

of

Me

dic

al S

cie

nce

s

(CU

CM

S)

S

arj

an

a M

ud

a F

arm

asi (k

ep

ujia

n)*

| B

ache

lor

of

Ph

arm

acy (

Hon

s)*

11

.

Un

ive

rsiti A

sia

Me

tro

po

lita

n (

AM

U)

(Ko

lej U

niv

ers

iti S

ain

s K

esih

ata

n M

aste

rskill

) A

sia

Metr

op

olit

an

Un

ive

rsity (

AM

U)

(Ma

ste

rskill

Un

ive

rsity C

olle

ge

of

He

alth

Scie

nce

s)

Sarj

an

a M

ud

a F

arm

asi (k

ep

ujia

n)

4+

0 d

en

ga

n L

a T

rop

e U

niv

ers

iti,

Austr

alia

B

ach

elo

r of

Ph

arm

acy (

Hon

s)

4+

0 w

ith

Univ

ers

ity L

a T

rop

e,

Au

str

alia

12

. U

niv

ers

iti M

ana

ge

me

nt

& S

cie

nce

(M

SU

)

Man

ag

em

en

t &

Scie

nce

Un

ive

rsity (

MS

U)

Sarj

an

a M

ud

a F

arm

asi (k

ep

ujia

n)*

| B

ache

lor

of

Ph

arm

acy (

Hon

s)*

13

. U

niv

ers

iti S

EG

I | S

EG

I U

niv

ers

ity

Sarj

an

a F

arm

asi (P

rog

ram

Be

rke

mb

ar

bers

am

a S

un

de

rla

nd

Un

ive

rsiti,

UK

2+

2)

Ma

ste

r of

Pha

rmacy (

2+

2 tw

inn

ing w

ith U

niv

ers

ity o

f S

und

erl

an

d,

UK

)

14

. U

niv

ers

iti M

ona

sh

Ka

mp

us M

ala

ysia

M

on

ash

Un

ive

rsity M

ala

ysia

Cam

pu

s

Sarj

an

a M

ud

a F

arm

asi (k

ep

ujia

n)

sam

a d

en

gan

pro

gra

m U

niv

ers

iti

Mo

na

sh

, A

ustr

alia

B

ach

elo

r of

Ph

arm

acy (

Hon

s)

sim

ilar

pro

gra

mm

e o

f M

on

ash

Un

ive

rsity,

Austr

alia

15

. U

niv

ers

iti M

AH

SA

| M

AH

SA

Un

ive

rsity

Sarj

an

a M

ud

a F

arm

asi (k

ep

ujia

n)

| B

ache

lor

of

Ph

arm

acy (

Hon

s)

L

AM

PIR

AN

5

| L

ap

or

an

T

ah

un

an

2

01

2

Bil

.

No

. In

sti

tus

i | In

sti

tuti

on

P

rog

ram

| P

rog

ram

me

8.

AIM

ST

Un

ivers

iti | A

IMS

T U

niv

ers

ity

Sarj

an

a M

uda

Fa

rma

si (k

ep

ujia

n)*

| B

ache

lor

of

Ph

arm

acy (

Hon

s)*

9.

Un

ive

rsiti N

ott

ing

ha

m K

am

pu

s M

ala

ysia

(U

NM

C)

Un

ive

rsity N

ott

ing

ha

m M

ala

ysia

Ca

mp

us (

UN

MC

)

Sarj

an

a F

arm

asi*

(2+

2 s

am

a d

eng

an

pro

gra

m N

ott

ing

ha

m U

niv

ers

iti)

Ma

ste

r in

Pha

rmacy 2

+2

sim

ilar

* p

rog

ram

me

of

Un

ive

rsity N

ott

ing

ha

m,

UK

10

. K

ole

j U

niv

ers

iti S

ain

s P

eru

ba

tan

Cyb

erj

aya

(C

UC

MS

) C

ybe

rja

ya U

niv

ers

ity C

olle

ge

of

Me

dic

al S

cie

nce

s

(CU

CM

S)

S

arj

an

a M

ud

a F

arm

asi (k

ep

ujia

n)*

| B

ache

lor

of

Ph

arm

acy (

Hon

s)*

11

.

Un

ive

rsiti A

sia

Me

tro

po

lita

n (

AM

U)

(Ko

lej U

niv

ers

iti S

ain

s K

esih

ata

n M

aste

rskill

) A

sia

Metr

op

olit

an

Un

ive

rsity (

AM

U)

(Ma

ste

rskill

Un

ive

rsity C

olle

ge

of

He

alth

Scie

nce

s)

Sarj

an

a M

ud

a F

arm

asi (k

ep

ujia

n)

4+

0 d

en

ga

n L

a T

rop

e U

niv

ers

iti,

Austr

alia

B

ach

elo

r of

Ph

arm

acy (

Hon

s)

4+

0 w

ith

Univ

ers

ity L

a T

rop

e,

Au

str

alia

12

. U

niv

ers

iti M

ana

ge

me

nt

& S

cie

nce

(M

SU

)

Man

ag

em

en

t &

Scie

nce

Un

ive

rsity (

MS

U)

Sarj

an

a M

ud

a F

arm

asi (k

ep

ujia

n)*

| B

ache

lor

of

Ph

arm

acy (

Hon

s)*

13

. U

niv

ers

iti S

EG

I | S

EG

I U

niv

ers

ity

Sarj

an

a F

arm

asi (P

rog

ram

Be

rke

mb

ar

bers

am

a S

un

de

rla

nd

Un

ive

rsiti,

UK

2+

2)

Ma

ste

r of

Pha

rmacy (

2+

2 tw

inn

ing w

ith U

niv

ers

ity o

f S

und

erl

an

d,

UK

)

14

. U

niv

ers

iti M

ona

sh

Ka

mp

us M

ala

ysia

M

on

ash

Un

ive

rsity M

ala

ysia

Cam

pu

s

Sarj

an

a M

ud

a F

arm

asi (k

ep

ujia

n)

sam

a d

en

gan

pro

gra

m U

niv

ers

iti

Mo

na

sh

, A

ustr

alia

B

ach

elo

r of

Ph

arm

acy (

Hon

s)

sim

ilar

pro

gra

mm

e o

f M

on

ash

Un

ive

rsity,

Austr

alia

15

. U

niv

ers

iti M

AH

SA

| M

AH

SA

Un

ive

rsity

Sarj

an

a M

ud

a F

arm

asi (k

ep

ujia

n)

| B

ache

lor

of

Ph

arm

acy (

Hon

s)

L

AM

PIR

AN

6

| L

ap

or

an

T

ah

un

an

2

01

2

Bil

.

No

. In

sti

tus

i | In

sti

tuti

on

P

rog

ram

| P

rog

ram

me

16

. U

niv

ers

iti T

aylo

r’s | T

aylo

r’s U

niv

ers

ity

Sarj

an

a M

ud

a F

arm

asi (k

ep

ujia

n)

| B

ache

lor

of

Ph

arm

acy (

Hon

s)

Sarj

an

a F

arm

asi (2

+2

) ke

rjasa

ma

de

ng

an

Ca

rdiff

Univ

ers

iti, U

K

Ma

ste

r of

Pha

rmacy (

2+

2)

in c

olla

bora

tio

n w

ith

Ca

rdiff U

niv

ers

ity, U

K

Page 55: program farmasi / pharmacy programme

54 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

L

AM

PIR

AN

7

| L

ap

or

an

T

ah

un

an

2

01

2

Tre

n P

en

cap

aia

n K

PI

200

9-2

01

2

(Tie

r 1

, 2

dan

3)

KP

I P

erf

orm

an

ce T

ren

d 2

00

9-2

01

2 (

Tie

r 1,

2 a

nd

3)

A. A

MA

LAN

DA

N P

ERKE

MBA

NG

AN

FA

RMA

SI |

PHA

RMA

CY

PRA

CTIC

E A

ND

DEVE

LOPM

ENT

BIL

. N

o.

KP

I K

PI

PE

NC

AP

AIA

N A

CH

IEV

EM

EN

TS

20

09

201

0

201

1

20

12

1.

B

ilan

ga

n h

osp

ital

da

n k

linik

kesih

ata

n y

an

g

me

na

wa

rka

n S

iste

m T

em

uja

nji

me

ng

am

bil

ub

at

di F

arm

asi

(Con

toh

: S

MS

&

Am

bil,

T

ele

fon

&A

mb

il,

Farm

asi

Pa

nd

u L

alu

, U

MP

1 M

ala

ysia

, dll)

ke

pa

da

p

esakit

ya

ng

m

en

erim

a

raw

ata

n

jan

gka p

an

jan

g

Nu

mb

er

of

Hosp

ita

ls

an

d

Hea

lth

C

linic

s

Off

eri

ng

App

oin

tme

nt

Syste

m f

or

obta

inin

g

refill

me

dic

ation

s (

eg

. S

MS

& T

ake

, C

all

&

Take

, D

rive T

hru

Pha

rmacy,

Dru

g T

hro

ug

h

Posta

l S

erv

ice

1M

ala

ysia

etc

)

87

ho

spita

l &

3

8 k

linik

ke

sih

ata

n

8

7 h

osp

ita

ls &

38

he

alth

clin

ics

S

AS

AR

AN

T

AR

GE

T:

60

ho

spita

l &

2

0 k

linik

ke

sih

ata

n

6

0 h

osp

ita

ls &

20

he

alth

clin

ics

13

1 h

ospita

l &

201

klin

ik k

esih

ata

n

1

31

ho

spita

ls &

2

01

he

alth c

linic

s

S

AS

AR

AN

T

AR

GE

T:

130

ho

sp

ital &

60

klin

ik k

esih

ata

n

1

30

ho

sp

itals

&

60

he

alth

clin

ics

386

klin

ik k

esih

ata

n

3

86

he

alth c

linic

s

S

AS

AR

AN

T

AR

GE

T:

380

klin

ik k

esih

ata

n

3

80

he

alth c

linic

s

46

5 k

linik

kesih

ata

n

46

5 h

ea

lth

clin

ics

S

AS

AR

AN

T

AR

GE

T:

45

0 k

linik

kesih

ata

n

45

0 h

ea

lth

clin

ics

2.

*P

era

tus

pre

skrip

si

did

isp

en

s

dala

m

tem

po

h 3

0 m

init

Cata

tan

: *M

ula

i 2010

, d

ipin

da

dari k

enyata

an a

sal:

“Pera

tus

Kaunte

r F

arm

asi

KK

M

yang

Berjaya

Mend

ispens U

bat

da

lam

T

em

poh 30 M

init S

ele

pas

Menerim

a P

reskripsi”.

*Perc

en

tag

e

of

pre

scri

ption

s

dis

pe

nse

d

with

in 3

0 m

inu

tes

No

te:

*Begin

nin

g

2010,

am

ended

from

th

e

orig

ina

l sta

tem

ent:

Perc

enta

ge

of

pharm

acy counte

rs

that

managed

to

dis

pense m

edic

atio

ns w

ithin

30 m

inute

s

92

.91

% k

au

nte

r fa

rma

si

9

2.9

1%

ph

arm

acy

co

unte

rs

S

AS

AR

AN

T

AR

GE

T:

80

%

kau

nte

r fa

rma

si

8

0%

ph

arm

acy

co

unte

rs

96

.6%

pre

skri

psi

9

6.6

% p

rescrip

tio

ns

S

AS

AR

AN

T

AR

GE

T:

10

0%

pre

skrip

si

10

0%

pre

scri

ptio

ns

96

.27

% p

reskrip

si

9

6.2

7%

pre

scri

ption

s

S

AS

AR

AN

T

AR

GE

T:

10

0%

pre

skrip

si

10

0%

pre

scri

ptio

ns

95.2

9%

pre

skri

psi

9

5.2

9%

p

rescri

ptio

ns

S

AS

AR

AN

T

AR

GE

T:

95

% p

reskri

psi

95%

pre

scri

ption

s

L

AM

PIR

AN

8

| L

ap

or

an

T

ah

un

an

2

01

2

BIL

. N

o.

KP

I K

PI

PE

NC

AP

AIA

N A

CH

IEV

EM

EN

TS

20

09

201

0

201

1

20

12

3.

P

era

tus

fasili

ti

farm

asi

ya

ng

m

ew

uju

dka

n

MT

AC

C

ata

tan

:

1:

Bila

ngan H

P berk

ura

ng daripada 40 kepada 38

sete

lah p

engecualia

n d

ibuat

bag

i H

ospita

l M

esra

Bukit

Padang d

an H

osp

ital Q

ueen E

liza

beth

II

2 :

Peru

bahan s

asara

n b

agi

suku t

ahun t

era

khir d

gn

mengu

bah

krite

ria

pe

lapora

n

dengan

han

ya

mengam

bil

kira

KK

ya

ng

mem

punya

i 2

Pegaw

ai

Farm

asi (

PF

) sahaja

H

U : H

ospita

l Uta

ma

HP

: H

ospita

l B

erp

akar

HX

P : H

ospita

l Tid

ak B

erp

akar

Perc

en

tag

e

of

ph

arm

acy

facili

tie

s

with

M

TA

C e

sta

blis

hm

en

t N

ote

: 1:

Num

ber

of

SP

reduced f

rom

40 to 3

8 a

fter

exclu

sio

n

of

Mesra

Bukit

Padang H

ospita

l and Q

ueen E

lizabeth

II H

ospital

2:

Change in

targ

et

for

last

quart

er

with

changin

g i

n

report

ing crite

ria due to

hea

lth clin

ics havin

g only

2

pharm

acis

ts p

ers

onnel

MH

: M

ain

Hospita

ls

SP

: S

pecia

list H

ospita

ls

HX

P : H

ospita

l Tid

ak B

erp

akar

NS

P : N

on S

pecia

list H

ospita

ls

10

0%

HU

| M

H

5

3.4

9%

HP

| S

P

S

AS

AR

AN

T

AR

GE

T:

10

0%

HU

| M

H

50

% H

P | S

P

10

0%

HU

| M

H

9

2.1

1%

HP

| S

P

9

9 K

K | H

C

S

AS

AR

AN

T

AR

GE

T:

10

0%

HU

| M

H

7

5%

HP

| S

P

4

0 K

K | H

C

10

0%

HU

| M

H

1

00

% H

P | S

P

2

02

KK

| H

C

S

AS

AR

AN

T

AR

GE

T:

10

0%

HU

| M

H

1

00

% H

P | S

P

1

10

KK

| H

C

10

0%

HU

| M

H

97

% H

P | S

P

(3

7/3

8)1

15

4 K

K2 |

HC

96

% H

XP

| N

SP

SA

SA

RA

N

TA

RG

ET

: 1

00

% H

U | M

H

1

00%

HP

| S

P

2

00

KK

| H

C

10

0%

HX

P | N

SP

L

AM

PIR

AN

8

| L

ap

or

an

T

ah

un

an

2

01

2

BIL

. N

o.

KP

I K

PI

PE

NC

AP

AIA

N A

CH

IEV

EM

EN

TS

20

09

201

0

201

1

20

12

3.

P

era

tus

fasili

ti

farm

asi

ya

ng

m

ew

uju

dka

n

MT

AC

C

ata

tan

:

1:

Bila

ngan H

P berk

ura

ng daripada 40 kepada 38

sete

lah p

engecualia

n d

ibuat

bag

i H

ospita

l M

esra

Bukit

Padang d

an H

osp

ital Q

ueen E

liza

beth

II

2 :

Peru

bahan s

asara

n b

agi

suku t

ahun t

era

khir d

gn

mengu

bah

krite

ria

pe

lapora

n

dengan

han

ya

mengam

bil

kira

KK

ya

ng

mem

punya

i 2

Pegaw

ai

Farm

asi (

PF

) sahaja

H

U : H

ospita

l Uta

ma

HP

: H

ospita

l B

erp

akar

HX

P : H

ospita

l Tid

ak B

erp

akar

Perc

en

tag

e

of

ph

arm

acy

facili

tie

s

with

M

TA

C e

sta

blis

hm

en

t N

ote

: 1:

Num

ber

of

SP

reduced f

rom

40 to 3

8 a

fter

exclu

sio

n

of

Mesra

Bukit

Padang H

ospita

l and Q

ueen E

lizabeth

II H

ospital

2:

Change in

targ

et

for

last

quart

er

with

changin

g i

n

report

ing crite

ria due to

hea

lth clin

ics havin

g only

2

pharm

acis

ts p

ers

onnel

MH

: M

ain

Hospita

ls

SP

: S

pecia

list H

ospita

ls

HX

P : H

ospita

l Tid

ak B

erp

akar

NS

P : N

on S

pecia

list H

ospita

ls

10

0%

HU

| M

H

5

3.4

9%

HP

| S

P

S

AS

AR

AN

T

AR

GE

T:

10

0%

HU

| M

H

50

% H

P | S

P

10

0%

HU

| M

H

9

2.1

1%

HP

| S

P

9

9 K

K | H

C

S

AS

AR

AN

T

AR

GE

T:

10

0%

HU

| M

H

7

5%

HP

| S

P

4

0 K

K | H

C

10

0%

HU

| M

H

1

00

% H

P | S

P

2

02

KK

| H

C

S

AS

AR

AN

T

AR

GE

T:

10

0%

HU

| M

H

1

00

% H

P | S

P

1

10

KK

| H

C

10

0%

HU

| M

H

97

% H

P | S

P

(3

7/3

8)1

15

4 K

K2 |

HC

96

% H

XP

| N

SP

SA

SA

RA

N

TA

RG

ET

: 1

00

% H

U | M

H

1

00%

HP

| S

P

2

00

KK

| H

C

10

0%

HX

P | N

SP

Page 56: program farmasi / pharmacy programme

55PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

L

AM

PIR

AN

8

| L

ap

or

an

T

ah

un

an

2

01

2

BIL

. N

o.

KP

I K

PI

PE

NC

AP

AIA

N A

CH

IEV

EM

EN

TS

20

09

201

0

201

1

20

12

3.

P

era

tus

fasili

ti

farm

asi

ya

ng

m

ew

uju

dka

n

MT

AC

C

ata

tan

:

1:

Bila

ngan H

P berk

ura

ng daripada 40 kepada 38

sete

lah p

engecualia

n d

ibuat

bag

i H

ospita

l M

esra

Bukit

Padang d

an H

osp

ital Q

ueen E

liza

beth

II

2 :

Peru

bahan s

asara

n b

agi

suku t

ahun t

era

khir d

gn

mengu

bah

krite

ria

pe

lapora

n

dengan

han

ya

mengam

bil

kira

KK

ya

ng

mem

punya

i 2

Pegaw

ai

Farm

asi (

PF

) sahaja

H

U : H

ospita

l Uta

ma

HP

: H

ospita

l B

erp

akar

HX

P : H

ospita

l Tid

ak B

erp

akar

Perc

en

tag

e

of

ph

arm

acy

facili

tie

s

with

M

TA

C e

sta

blis

hm

en

t N

ote

: 1:

Num

ber

of

SP

reduced f

rom

40 to 3

8 a

fter

exclu

sio

n

of

Mesra

Bukit

Padang H

ospita

l and Q

ueen E

lizabeth

II H

ospital

2:

Change in

targ

et

for

last

quart

er

with

changin

g i

n

report

ing crite

ria due to

hea

lth clin

ics havin

g only

2

pharm

acis

ts p

ers

onnel

MH

: M

ain

Hospita

ls

SP

: S

pecia

list H

ospita

ls

HX

P : H

ospita

l Tid

ak B

erp

akar

NS

P : N

on S

pecia

list H

ospita

ls

10

0%

HU

| M

H

5

3.4

9%

HP

| S

P

S

AS

AR

AN

T

AR

GE

T:

10

0%

HU

| M

H

50

% H

P | S

P

10

0%

HU

| M

H

9

2.1

1%

HP

| S

P

9

9 K

K | H

C

S

AS

AR

AN

T

AR

GE

T:

10

0%

HU

| M

H

7

5%

HP

| S

P

4

0 K

K | H

C

10

0%

HU

| M

H

1

00

% H

P | S

P

2

02

KK

| H

C

S

AS

AR

AN

T

AR

GE

T:

10

0%

HU

| M

H

1

00

% H

P | S

P

1

10

KK

| H

C

10

0%

HU

| M

H

97

% H

P | S

P

(3

7/3

8)1

15

4 K

K2 |

HC

96

% H

XP

| N

SP

SA

SA

RA

N

TA

RG

ET

: 1

00

% H

U | M

H

1

00%

HP

| S

P

2

00

KK

| H

C

10

0%

HX

P | N

SP

L

AM

PIR

AN

8

| L

ap

or

an

T

ah

un

an

2

01

2

BIL

. N

o.

KP

I K

PI

PE

NC

AP

AIA

N A

CH

IEV

EM

EN

TS

20

09

201

0

201

1

20

12

3.

P

era

tus

fasili

ti

farm

asi

ya

ng

m

ew

uju

dka

n

MT

AC

C

ata

tan

:

1:

Bila

ngan H

P berk

ura

ng daripada 40 kepada 38

sete

lah p

engecualia

n d

ibuat

bag

i H

ospita

l M

esra

Bukit

Padang d

an H

osp

ital Q

ueen E

liza

beth

II

2 :

Peru

bahan s

asara

n b

agi

suku t

ahun t

era

khir d

gn

mengu

bah

krite

ria

pe

lapora

n

dengan

han

ya

mengam

bil

kira

KK

ya

ng

mem

punya

i 2

Pegaw

ai

Farm

asi (

PF

) sahaja

H

U : H

ospita

l Uta

ma

HP

: H

ospita

l B

erp

akar

HX

P : H

ospita

l Tid

ak B

erp

akar

Perc

en

tag

e

of

ph

arm

acy

facili

tie

s

with

M

TA

C e

sta

blis

hm

en

t N

ote

: 1:

Num

ber

of

SP

reduced f

rom

40 to 3

8 a

fter

exclu

sio

n

of

Mesra

Bukit

Padang H

ospita

l and Q

ueen E

lizabeth

II H

ospital

2:

Change in

targ

et

for

last

quart

er

with

changin

g i

n

report

ing crite

ria due to

hea

lth clin

ics havin

g only

2

pharm

acis

ts p

ers

onnel

MH

: M

ain

Hospita

ls

SP

: S

pecia

list H

ospita

ls

HX

P : H

ospita

l Tid

ak B

erp

akar

NS

P : N

on S

pecia

list H

ospita

ls

10

0%

HU

| M

H

5

3.4

9%

HP

| S

P

S

AS

AR

AN

T

AR

GE

T:

10

0%

HU

| M

H

50

% H

P | S

P

10

0%

HU

| M

H

9

2.1

1%

HP

| S

P

9

9 K

K | H

C

S

AS

AR

AN

T

AR

GE

T:

10

0%

HU

| M

H

7

5%

HP

| S

P

4

0 K

K | H

C

10

0%

HU

| M

H

1

00

% H

P | S

P

2

02

KK

| H

C

S

AS

AR

AN

T

AR

GE

T:

10

0%

HU

| M

H

1

00

% H

P | S

P

1

10

KK

| H

C

10

0%

HU

| M

H

97

% H

P | S

P

(3

7/3

8)1

15

4 K

K2 |

HC

96

% H

XP

| N

SP

SA

SA

RA

N

TA

RG

ET

: 1

00

% H

U | M

H

1

00%

HP

| S

P

2

00

KK

| H

C

10

0%

HX

P | N

SP

Page 57: program farmasi / pharmacy programme

56 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

L

AM

PIR

AN

9

| L

ap

or

an

T

ah

un

an

2

01

2

B. P

ENG

UATK

UASA

AN

FA

RMA

SI |

PHA

RMA

CY

ENFO

RCEM

ENT

BIL

.

No

.

KP

I

KP

I

PE

NC

AP

AIA

N A

CH

IEV

EM

EN

TS

2

00

9

20

10

20

11

20

12

1.

P

era

tus p

en

ge

lua

ran

le

se

n/p

erm

it b

aru

ya

ng

dik

elu

ark

an

di

ba

wa

h

Akta

R

acu

n

19

52

dala

m t

em

po

h 1

0 h

ari b

eke

rja

Issu

an

ce

of

lice

nse/p

erm

it (

un

de

r P

ois

on

Act

195

2)

with

in 1

0 w

ork

ing d

ays

91

.2%

SA

SA

RA

N

TA

RG

ET

: 9

0%

97

.7%

SA

SA

RA

N

TA

RG

ET

: 90

%

99

.7%

SA

SA

RA

N

TA

RG

ET

: 1

00%

99

.1%

SA

SA

RA

N

TA

RG

ET

: 1

00

%

2.

P

era

tus

inte

llig

ence

sa

mple

ya

ng

p

ositif

me

ng

an

dun

gi

ba

ha

n

terl

ara

ng

b

erb

an

din

g

jum

lah

sa

mp

el p

rod

uk y

an

g d

iuji

Inte

llige

nce

sa

mp

les

teste

d

po

sitiv

e

for

pro

hib

ited

su

bsta

nces

56

%

S

AS

AR

AN

T

AR

GE

T:

70

%

62

.1%

SA

SA

RA

N

TA

RG

ET

: 70

%

81

.1%

SA

SA

RA

N

TA

RG

ET

: 7

0%

80

.2%

SA

SA

RA

N

TA

RG

ET

: 7

0%

3.

P

era

tus s

erb

ua

n y

an

g b

erj

aya

un

tuk d

iam

bil

tind

aka

n

un

dan

g-u

nd

an

g

darip

ad

a

jum

lah

serb

ua

n y

an

g d

ijala

nka

n

Su

cce

ssfu

l ra

ids r

esu

ltin

g in

le

ga

l a

ctio

ns

94

.4%

SA

SA

RA

N

TA

RG

ET

: 7

5%

94

.5%

SA

SA

RA

N

TA

RG

ET

: 75

%

98

.2%

SA

SA

RA

N

TA

RG

ET

: 9

5%

99

.6%

SA

SA

RA

N

TA

RG

ET

: 9

5%

Page 58: program farmasi / pharmacy programme

57PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

L

AM

PIR

AN

1

0 | L

ap

or

an

T

ah

un

an

2

01

2

C. B

AHA

GIA

N D

ASA

R DA

N P

ENG

URUS

AN

FA

RMA

SI |

PHA

RMA

CY

POLIC

Y A

ND

MA

NA

GEM

ENT

BIL

.

No

.

KP

I

KP

I

PE

NC

AP

AIA

N A

CH

IEV

EM

EN

TS

2

00

9

2

010

2

01

1

20

12

1.

P

era

tus

Pe

ga

wa

i F

arm

asi

yan

g

me

nca

pa

i

ma

ta m

inim

um

C

PD

ya

ng

d

ite

tapka

n d

ala

m

ma

sa s

eta

hu

n:

Ja

nu

ari

– M

ac

: 1

0 m

ata

Ja

nu

ari

– J

un

: 2

0 m

ata

Ja

nu

ari

– S

ep

tem

be

r :

30

mata

Ja

nu

ari

– D

ise

mb

er

:

40 m

ata

Pe

rce

nta

ge

o

f p

harm

acis

ts

me

eting

th

e

min

imu

m C

PD

po

ints

se

t in

a y

ea

r:

Ja

nu

ary

– M

arc

h

:

10

po

ints

Ja

nu

ary

– J

un

e

: 2

0 p

oin

ts

Ja

nu

ary

– S

ep

tem

ber:

30

po

ints

Ja

nu

ary

– D

ecem

be

r : 4

0 p

oin

ts

100

%

S

AS

AR

AN

T

AR

GE

T:

10

0%

PF

di Ib

u

Pe

jab

at

BP

F d

an

B

PF

K

1

00

% p

harm

acis

ts a

t P

SD

an

d B

PF

K H

Q

97

.7%

SA

SA

RA

N

TA

RG

ET

: 1

00

% P

F d

i Ib

u

Pe

jab

at

BP

F d

an

B

PF

K

1

00

% p

harm

acis

ts

at

PS

D a

nd

BP

FK

H

Q

99

%

S

AS

AR

AN

T

AR

GE

T:

100

% P

F s

elu

ruh

ne

ga

ra

1

00

% p

ha

rma

cis

t na

tio

nw

ide

99

.7%

SA

SA

RA

N

TA

RG

ET

: 10

0%

PF

selu

ruh

n

eg

ara

10

0%

pha

rmacis

ts

na

tio

nw

ide

2.

P

era

tus

pe

rbe

lan

jaa

n

p

eru

ntu

ka

n

latih

an

d

ala

m P

erk

hid

ma

tan

P

erc

en

tag

e

of

expe

nd

iture

fo

r o

rga

niz

ing

tr

ain

ing

in t

he

co

un

try

99

.3%

SA

SA

RA

N

TA

RG

ET

:

95

%

81

.65%

SA

SA

RA

N

TA

RG

ET

:

95

%

Dig

ugu

rka

n d

an

dig

an

tika

n d

en

ga

n

ind

ika

tor

(3)

Dro

ppe

d a

nd

re

pla

ce

d w

ith in

dic

ato

r (3

)

Page 59: program farmasi / pharmacy programme

58 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

L

AM

PIR

AN

1

1 | L

ap

or

an

T

ah

un

an

2

01

2

BIL

.

No

.

KP

I

KP

I

PE

NC

AP

AIA

N A

CH

IEV

EM

EN

TS

2

00

9

2

010

2

01

1

20

12

3.

P

era

tus

pe

rbe

lan

jaa

n

ke

se

luru

ha

n

be

lan

ja

me

ng

uru

s

(B42

) B

ah

ag

ian

P

erk

hid

ma

tan

Farm

asi (ib

u p

eja

bat)

Ja

nu

ari

– M

ac

: 2

0%

Ja

nu

ari

– J

un

:

45

%

Ja

nu

ari

– S

ep

tem

be

r : 7

5%

Ja

nu

ari

– D

ise

mb

er

: 1

00

%

Ca

tata

n:

Ind

ika

tor

ini

mula

dip

an

tau s

eb

ag

ai

KP

I pa

da

tah

un 2

01

1

Pe

rce

nta

ge

of to

tal exp

en

ditu

re P

SD

(H

Q)

Ja

nu

ary

– M

arc

h

: 2

0%

Ja

nu

ary

– J

un

e

:

45

%

Ja

nu

ary

– S

ep

tem

ber

: 7

5%

Ja

nu

ary

– D

ecem

be

r : 1

00

%

No

te:

Ind

ica

tor

ha

d b

ee

n m

on

ito

red a

s K

PI

sin

ce

201

1

Ke

selu

ruh

an

T

ota

l :

97

.87

%

D

asa

r &

P

en

gu

rusa

n

Farm

asi

P

harm

acy P

olic

y &

M

ana

ge

me

nt:

97

.44

%

A

ma

lan

&

Pe

rke

mb

an

ga

n

Farm

asi

P

harm

acy P

ractice

&

De

ve

lop

me

nt:

96

.80

%

P

en

gu

atk

uasa

an

F

arm

asi

P

ha

rma

cy

En

forc

em

en

t:

98

.79

%

S

AS

AR

AN

T

AR

GE

T:

>9

5%

Ke

se

luru

ha

n

To

tal:

9

9.1

1%

Dasa

r &

P

en

gu

rusa

n

Fa

rma

si

P

ha

rma

cy P

olic

y &

M

an

age

me

nt:

9

9.4

1%

Am

ala

n &

P

erk

em

ba

ng

an

F

arm

asi

P

ha

rma

cy P

ractice

&

Deve

lop

me

nt:

98

.61

%

P

en

gu

atk

ua

saa

n

Fa

rma

si

P

harm

acy

En

forc

em

en

t:

99

.16%

SA

SA

RA

N

TA

RG

ET

: >

95%

Ke

se

luru

ha

n

To

tal:

9

8.4

0%

Dasa

r &

P

en

gu

rusan

F

arm

asi

P

ha

rma

cy P

olic

y &

M

an

ag

em

en

t:

98

.25%

Am

ala

n &

P

erk

em

ba

ng

an

F

arm

asi

P

ha

rma

cy P

olic

y &

M

an

ag

em

en

t:

96

.72

%

P

en

gu

atk

ua

saa

n

Fa

rma

si

P

harm

acy

En

forc

em

en

t:

99

.93%

SA

SA

RA

N

TA

RG

ET

: >

95%

Ke

se

luru

ha

n

To

tal:

9

8.8

1%

Da

sa

r &

P

en

gu

rusan

F

arm

asi

P

harm

acy P

olic

y &

M

an

ag

em

en

t:

99

.0%

Am

ala

n

&P

erk

em

ba

ng

an

F

arm

asi

P

harm

acy P

ractice

&

de

ve

lop

me

nt:

99.6

4%

Pe

ng

ua

tku

asa

an

F

arm

asi

P

ha

rma

cy

En

forc

em

en

t:

99.4

6%

SA

SA

RA

N

TA

RG

ET

: >

95

%

Page 60: program farmasi / pharmacy programme

59PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

L

AM

PIR

AN

1

2 | L

ap

or

an

T

ah

un

an

2

01

2

BIL

.

No

.

KP

I

KP

I

PE

NC

AP

AIA

N A

CH

IEV

EM

EN

TS

2

00

9

2

010

2

01

1

20

12

4.

*P

era

tus

Peg

aw

ai

Fa

rma

si

yan

g

me

nd

ap

at

Ija

za

h

Sa

rja

na

/D

okto

r F

als

afa

h

se

lep

as

me

neri

ma

C

uti

Be

laja

r B

erg

aji

Pen

uh

(de

ng

an

ata

u t

an

pa

bia

sis

wa

)

Ca

tata

n:

*Mula

i 2

011

, d

ipin

da

dari k

enyata

an a

sal:

“Bila

ngan P

egaw

ai F

arm

asi yang M

ela

nju

tkan P

eng

ajia

n

ke

Peringkat

Ijaza

h

Lan

juta

n

Sarjana

dan

Dokto

r

Fals

afa

h d

ala

m P

elb

aga

i B

idang d

an K

epakara

n”.

*Perc

en

tag

e

of

Ph

arm

acis

ts

wh

o

ea

rns

a

Ma

ste

rs/P

hD

aft

er

rece

ivin

g

full

pa

id

stu

dy

lea

ve

(w

ith

or

with

ou

t sch

ola

rsh

ip)

No

te:

*Fro

m 2

011, as a

mended fro

m o

rigin

al s

tate

ment:

“The num

ber

of

pharm

acis

ts w

ho purs

ue an M

BA

and

PhD

in

various fie

lds a

nd

expert

ise”

46

%

S

AS

AR

AN

T

AR

GE

T:

20

%

17

5

S

AS

AR

AN

T

AR

GE

T :

15

%

10

0%

SA

SA

RA

N

TA

RG

ET

:

95

%

100

%

S

AS

AR

AN

T

AR

GE

T :

9

5%

Page 61: program farmasi / pharmacy programme

60 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

L

AM

PIR

AN

1

3 | L

ap

or

an

T

ah

un

an

2

01

2

D. B

IRO

PEN

GA

WA

LAN

FA

RMA

SEUT

IKA

L KE

BAN

GSA

AN

| N

ATIO

NA

L PH

ARM

AC

EUTIC

AL

CO

NTR

OL

BURE

AU

BIL.

N

o.

KPI

KPI

PEN

CAPA

IAN

ACH

IEVE

MEN

TS

2009

20

10

2011

2012

1.

*Pe

ratu

s

pe

nin

gkata

n

pe

mb

eri

an

Lese

n/K

eb

en

ara

n

me

ng

ilan

g

bag

i p

rod

uk

farm

ase

utika

l, t

radis

ion

al da

n k

osm

etik

(p

en

ing

kata

n a

da

lah

be

rda

sark

an

pu

rata

3

tah

un

se

be

lum

nya

) C

ata

tan

*M

ula

i 2010

dip

inda d

ari

ind

ikato

r asal:

“Bila

ngan

Lesen/

Kebenara

n

Mengila

ng

Bag

i P

roduk

Farm

aseutik

al, T

radis

iona

l D

an K

osm

etik

”.

*Issu

ance

of

lice

nce/p

erm

it f

or

pro

du

ctio

n o

f p

ha

rma

ce

utica

ls,

trad

itio

na

l a

nd

co

sm

etic

pro

du

cts

(in

cre

ase is b

ase

d o

n t

he

pre

vio

us 3

ye

ar

ave

rag

e)

No

te

*Sin

ce 2

01

0, as a

mended fro

m o

rigin

al s

tate

ment:

“Num

ber

of

pro

ductio

n lic

ense/p

erm

it fo

r pharm

aceutic

al,

traditio

na

l and c

osm

etic

pro

ducts

”.

487

SA

SA

RA

N

TA

RG

ET

:

380

51

9

(25

.4%

pe

nin

gka

tan

)

(25

.4%

incre

ase

)

SA

SA

RA

N

TA

RG

ET

:

11

%

pe

nin

gkata

n

(1

1%

in

cre

ase

)

(~4

60

lese

n/

ke

be

nara

n

me

ng

ilan

g )

(~46

0 p

rod

uctio

n

lice

nse

/pe

rmit)

55

5

(19

.9%

pe

nin

gka

tan

)

(19.9

% in

cre

ase

)

SA

SA

RA

N

TA

RG

ET

:

14

%

pe

nin

gkata

n

(1

4%

in

cre

ase

)

(~5

30

lese

n/

ke

be

na

ran

m

eng

ilan

g)

(~

53

0 p

rod

uctio

n

lice

nse

/perm

it)

575

(1

0.6

%

pe

nin

gkata

n)

(1

0.6

% in

cre

ase)

S

AS

AR

AN

T

AR

GE

T:

7.5

%

pe

nin

gka

tan

(7.5

% in

cre

ase

)

(~5

60

le

se

n/

ke

ben

ara

n

men

gila

ng)

(~

56

0 p

rod

uctio

n

lice

nse/p

erm

it)

2.

Bila

ng

an

p

rod

uk

be

rda

fta

r d

an

ko

sm

etik

bern

otifika

si

da

lam

p

asa

ran

ya

ng

d

ipa

nta

u

bag

i tu

jua

n

kese

lam

ata

n d

an

ku

alit

i N

um

be

r of

no

tifie

d re

gis

tere

d a

nd

co

sm

etic

pro

du

cts

in

th

e m

ark

et

wh

ich

is m

on

ito

red

for

safe

ty a

nd

qua

lity

2,9

31

pro

du

k

2,9

31

pro

ducts

SA

SA

RA

N

TA

RG

ET

: 2,5

00

3,0

13

pro

du

k

3,0

13

pro

du

cts

SA

SA

RA

N

TA

RG

ET

: 2

,50

0

3,2

84

pro

du

k

3,2

84

pro

du

cts

SA

SA

RA

N

TA

RG

ET

: 3

,00

0

3,3

05

pro

du

k

3,3

05

pro

du

cts

SA

SA

RA

N

TA

RG

ET

: 3

,30

0

L

AM

PIR

AN

1

4 | L

ap

or

an

T

ah

un

an

2

01

2

BIL.

N

o.

KPI

KPI

PEN

CAPA

IAN

ACH

IEVE

MEN

TS

2009

20

10

2011

2012

3.

Pe

ng

ga

lakka

n

pe

lap

ora

n

Ad

vers

e

Dru

g

Re

actio

n (

AD

R).

P

rom

otin

g

rep

ort

ing

o

f A

dvers

e

Dru

g

Re

actio

n (

AD

R).

5,8

50

SA

SA

RA

N

TA

RG

ET

: 5,0

00

7,0

79

SA

SA

RA

N

TA

RG

ET

: 7

,20

0

(~ 2

00

AD

R p

er

juta

po

pu

lasi)

(~2

00

AD

Rs p

er

mill

ion

po

pula

tion

)

9,3

85

SA

SA

RA

N

TA

RG

ET

: 9

,50

0

(~ 2

00

AD

R p

er

juta

po

pu

lasi)

(~2

00

AD

Rs p

er

mill

ion

po

pula

tion

)

10

,10

2

S

AS

AR

AN

T

AR

GE

T:

9,5

00

(

~ 2

00

AD

R p

er

juta

po

pula

si)

(~

20

0 A

DR

s p

er

mill

ion

po

pu

latio

n)

Page 62: program farmasi / pharmacy programme

61PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

L

AM

PIR

AN

1

5 | L

ap

or

an

T

ah

un

an

2

01

2

Jad

ual

3:

Bilan

gan

Klin

ik K

esih

ata

n Y

an

g M

en

aw

ark

an

Sis

tem

Te

mu

jan

ji M

en

ga

mb

il U

bat

di

Fa

rmas

i k

ep

ad

a p

esak

it y

an

g

men

eri

ma r

aw

ata

n jan

gk

a p

an

jan

g b

ag

i ta

hu

n 2

010

-2012

Tab

le 3

: N

um

ber

of

He

alt

h C

lin

ic P

harm

acie

s O

fferi

ng

Ph

arm

ac

y A

pp

oin

tmen

ts S

yste

m f

or

pati

en

ts r

ece

ivin

g l

on

g-t

erm

tre

atm

en

t fo

r 2

010-2

012

Tah

un

| Y

ear

20

10

20

11

201

2

Bil.

Klin

ik K

esih

ata

n y

an

g m

en

aw

ark

an S

iste

m T

em

uja

nji

Men

ga

mb

il U

bat

di

Farm

asi

kep

ad

a

pe

sa

kit

ya

ng

men

eri

ma

ra

wa

tan

ja

ng

ka

pa

nja

ng.

Nu

mb

er

of

He

alth

Clin

ic O

ffe

rin

g P

ha

rma

cy A

pp

oin

tmen

ts

Syste

m f

or

Pa

tie

nts

Re

ceiv

ing

Lo

ng-T

erm

Tre

atm

en

t

20

1

386

4

65

Jad

ual

4:

Pe

ratu

s p

resk

rip

si

ya

ng

Berj

aya

did

isp

en

dala

m m

asa 3

0 m

init

(20

10-2

012

)

Tab

le 4

: P

erc

en

tag

e o

f P

res

cri

pti

on

s d

isp

en

sed

wit

hin

30 m

inu

tes (

201

0-2

01

2)

Tah

un

| Y

ear

20

10

201

1

201

2

Pe

ratu

s P

reksrip

si

ya

nd

did

isp

ens

Perc

enta

ge o

f

Pre

scri

ption

s

dis

pen

sed

96

.6%

96

.3%

95

.29

%

Page 63: program farmasi / pharmacy programme

62 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

L

AM

PIR

AN

1

6 | L

ap

or

an

T

ah

un

an

2

01

2

Ra

jah

2 :

Ak

tivit

i P

en

ilaia

n F

arm

ako

eko

no

mik

Fig

ure

2:

Ph

arm

aco

eco

no

mic

s E

valu

ati

on

Acti

vit

ies

* P

erb

andin

gan u

ba

t :

Bila

ngan u

bat

(Pro

form

a B

dan P

rofo

rma D

) ya

ng d

ibua

t perb

andin

gan d

enga

n a

ltern

ative s

edia

ada d

ala

m F

orm

ula

ri U

bat

Kem

ente

rian K

esih

ata

n M

ala

ysia

(FU

KK

M)

*Dru

g C

om

parison: N

o. of dru

gs (

Pro

form

a B

and P

rofo

rma D

) com

pare

d w

ith a

ltern

ativ

es r

eadily

availa

ble

in

the

Min

istr

y o

f H

ealth

Dru

g F

orm

ula

ry

* D

rug R

evie

w: B

ilang

an u

ba

t ya

ng

dib

uat pen

ilaia

n lengkap d

ari

segi k

esela

mata

n, efikasi dan

cost-

effectiv

eness b

agi ubat baru

(P

rofo

rma D

)

* D

rug R

evie

w: N

o. of new

dru

gs m

ade a

com

ple

te e

valu

ation o

f safe

ty, e

ffic

acy a

nd c

ost-

effectiv

eness (

Pro

form

a D

)

2008

2009

2010

2011

2012

Perb

andi

ngan

uba

t 27

132

722

227

122

1

Drug

revi

ew31

3930

4138

051015202530354045

050100

150

200

250

300

350

Bilangan drug review

Bilanagan perbandingan ubat

Page 64: program farmasi / pharmacy programme

63PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

L

AM

PIR

AN

1

7 | L

ap

or

an

T

ah

un

an

2

01

2

AKT

IVITI

PEN

GUA

TKUA

SAA

N F

ARM

ASI

ENFO

RCEM

ENT P

HARM

AC

Y A

CTIV

ITIES

JU

ML

AH

NIL

AI

RA

MP

AS

AN

PE

NG

UA

TK

UA

SA

AN

FA

RM

AS

I 2

01

0-2

012

V

AL

UE

OF

IT

EM

S S

EIZ

ED

BY

PH

AR

MA

CY

EN

FO

RC

EM

EN

T 2

010

-2012

Ram

pasa

n (

RM

) M

en

gik

ut S

erb

uan,

Pem

eri

ksaan d

an

Pin

tu M

asuk T

ah

un

20

10

-201

2

Valu

e S

eiz

ed

(R

M)

acco

rdin

g to

Raid

ing,

Insp

ectio

n a

nd

Entr

y P

oin

t fo

r yea

r 2

010-2

01

2

Tah

un

Y

ear

Se

rbu

an

R

aid

P

em

eri

ks

aan

In

sp

ec

tio

n

Pin

tu M

asu

k

En

try

Po

int

Ju

mla

h

To

tal

Bil

. N

o. o

f It

em

s

Nila

i (R

M)

Va

lue (

RM

) B

il.

No

. o

f It

em

s

Nil

ai

(RM

) V

alu

e (

RM

) B

il.

No

. o

f It

em

s

Nil

ai (R

M)

Va

lue (

RM

) B

il.

No

. o

f It

em

s

Nila

i (R

M)

Va

lue (

RM

)

201

0

16,8

62

22

,00

0,0

47

6,0

39

37

1,7

35

6,8

69

1,7

56

,563

29

,770

24,1

28,3

45

201

1

22,9

70

27

,46

1,9

97

7,8

97

70

8,1

52

7,4

50

2,4

36

,019

38

,317

30,6

06,1

68

201

2

25,2

79

23

,36

1,0

91

4,5

67

35

5,6

50

14,8

11

2,6

19

,048

44

,657

26,3

35,7

89

L

AM

PIR

AN

1

8 |

La

po

ra

n

Ta

hu

na

n

20

12

Ram

pasa

n M

en

gik

ut K

ate

go

ri P

roduk T

ah

un

20

10

-201

2

Valu

e S

eiz

ed

(R

M)

acco

rdin

g to

Pro

du

k C

ate

go

ry f

or

ye

ar

20

10

-201

2

Ta

hu

n

Ye

ar

Kelu

ara

n B

erd

aft

ar

Reg

iste

red

Pro

du

cts

(A

, X

, T

, K

)

Kelu

ara

n T

idak

Be

rdaft

ar

Un

reg

iste

red

Pro

du

cts

(A

, X

, T

, K

, la

in-l

ain

/ o

thers

)

Lain

-Lain

* O

thers

* J

um

lah

T

ota

l

Bil

. N

o. o

f It

em

s

Nila

i (R

M)

Valu

e (

RM

) B

il.

No

. o

f It

em

s

Nil

ai (R

M)

Va

lue (

RM

) B

il.

No

. o

f It

em

s

Nila

i (R

M)

Valu

e (

RM

) B

il.

No

. o

f It

em

s

Nil

ai (R

M)

Va

lue (

RM

)

20

10

4,8

72

2,3

86,1

19

24,8

52

21

,569

,31

0

46

17

2,9

16

29,7

70

24

,128

,34

5

20

11

3,9

80

6,9

74,3

60

33,2

94

22

,534

,94

3

1,0

43

1,0

96,8

65

38,3

17

30

,606

,16

8

20

12

4,5

01

2,5

71,0

28

40,0

06

23

,72

7,5

75

15

0

37

,18

6

44,6

57

26

,335

,78

9

A =

Racu

n, X

= O

TC

, T

= T

radis

ion

al, K

= K

osm

etik;

Lain

-lain

: V

ete

rinar,

Pre

ku

rsor,

Ba

han

Kim

ia, B

aha

n M

enta

h,

lain

-lain

A

= P

ois

on,

X =

OT

C,

T =

Tra

ditio

nal, K

= C

osm

etic;

Oth

ers

: V

ete

rina

ry,

Pre

curs

or,

Ch

em

ical, P

ha

rma

ce

utical R

aw

Mate

ria

l, e

tc.

Page 65: program farmasi / pharmacy programme

64 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

L

AM

PIR

AN

1

9 | L

ap

or

an

T

ah

un

an

2

01

2

PRO

SEC

UTIO

N |

PEN

DAKW

AA

N

Pen

da

kw

aan

ad

ala

h b

erd

asa

rka

n e

mp

at

akta

ya

ng

uta

ma

sep

ert

i d

i b

aw

ah

. S

ep

an

jan

g t

ah

un 2

01

2,

se

jum

lah 1

,05

7 k

es t

ela

h s

ele

sa

i d

ida

kw

a

de

ng

an

ju

mla

h k

utip

an

de

nd

a s

eb

an

ya

k R

M3,3

83

,20

0.0

0.

Ca

se

s w

ere

pro

secu

ted

ba

se

d o

n f

ou

r m

ain

acts

. A

to

tal

of

1,0

57 c

ase

s w

ere

co

mp

lete

ly p

rose

cute

d i

n 2

01

2 w

ith

th

e t

ota

l co

llectio

n o

f R

M

3,3

83,2

00

.00

of

fin

es c

olle

cte

d.

PE

ND

AK

WA

AN

(S

EL

ES

AI)

BE

RD

AS

AR

KA

N A

KT

A D

AN

NE

GE

RI

(20

12

)

PR

OS

EC

UT

ION

(C

OM

PL

ET

ED

) B

Y A

CT

S A

ND

ST

AT

ES

(2

01

2)

AK

TA

A

CT

Ak

ta

Ra

cu

n

195

2

Po

iso

n

Act

19

52

Ak

ta R

acu

n

19

52

(B

ah

an

P

sik

otr

op

ik)

Po

iso

n A

ct

195

2

(Ps

ych

otr

op

ic

Su

bs

tan

ces)

Ak

ta

Ju

ala

n

Dad

ah

1

95

2

Sa

les o

f D

rug

A

cts

1

95

2

Ak

ta U

bat

(Ikla

n &

Ju

ala

n)

195

6

Me

dic

ine A

ct

(Sale

s a

nd

A

dv

ert

isem

en

t)

195

6

Akta

P

en

daft

ara

n

Ah

li

Fa

rma

si

19

51

R

eg

istr

ati

on

o

f P

ha

rmac

ist

Ac

t 1

95

1

JU

ML

AH

T

OT

AL

Bil

. K

es

No

. o

f c

as

e

40

4

46

5

53

54

0

1,0

57

K

uti

pan

D

en

da

Fin

e

Co

lle

cti

on

67

0,4

00

17

1,8

00

2,3

60

,050

18

0,9

50

0

3,3

83

,200

Page 66: program farmasi / pharmacy programme

65PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

L

AM

PIR

AN

2

0 | L

ap

or

an

T

ah

un

an

2

01

2

PELE

SEN

AN

DA

N K

AW

ALA

N B

AHA

N |

LIC

ENSI

NG

& S

UBST

AN

CES

CO

NTR

OL

Je

nis

da

n b

ila

ng

an

le

se

n/p

erm

it y

an

g d

ike

lua

rka

n o

leh

Ca

wa

ng

an

Pe

ng

ua

tku

asa

an

Ne

ge

ri d

i se

pa

nja

ng

ta

hu

n 2

01

2 b

erb

an

din

g d

en

ga

n

tah

un

20

10

da

n 2

01

1.

Th

e t

yp

es a

nd

nu

mb

er

of

licen

ce

s issu

ed

by S

tate

PE

Bs in 2

01

2 a

s c

om

pa

red t

o 2

01

0 a

nd

20

11.

Jen

is L

es

en

/ P

erm

it

Typ

e o

f L

icen

ce/ P

erm

it

Bil

Le

sen

/ P

erm

it

N

um

ber

of

Lic

en

ce

/Perm

it

20

10

2

01

1

20

12

Le

se

n R

acu

n J

en

is A

/P

ois

on

Lic

en

ce

Typ

e A

3,1

87

3

,31

4

3,8

19

Le

se

n R

acu

n J

en

is B

/ P

ois

on

Lic

en

ce

Typ

e B

1,6

68

1

70

8

1,8

11

Le

se

n R

acu

n J

en

is D

/ P

ois

on

Lic

en

ce

Typ

e D

9

-

-

Le

se

n R

acu

n J

en

is E

/ P

ois

on

Lic

en

ce

Typ

e E

3

0

28

3

5

Perm

it N

aO

H/

Na

OH

Pe

rmit

1,9

87

2

,11

6

2,2

56

Perm

it P

sik

otr

op

ik /

Psych

otr

op

ic P

erm

it

- 3

53

3

95

Keb

en

ara

n im

po

rt d

ad

ah

berb

ah

aya/

Impo

rt

Auth

ori

sa

tion

Fo

r D

ang

ero

us D

rug

16

5

20

4

18

4

Keb

en

ara

n e

ksp

ort

da

da

h b

erb

ah

aya/

Exp

ort

A

uth

ori

sa

tion

Fo

r D

ang

ero

us D

rug

2

5

22

1

6

Keb

en

ara

n im

po

rt b

ah

an

psik

otr

op

ik/ Im

po

rt

Auth

ori

sa

tion

Fo

r P

sycho

tro

pic

Sub

sta

nce

s

24

6

26

6

20

6

Keb

en

ara

n e

ksp

ort

ba

ha

n p

sik

otr

op

ik/

Exp

ort

A

uth

ori

sa

tion

Fo

r P

sycho

tro

pic

Sub

sta

nce

s

64

41

3

0

Jum

lah

& F

ee D

ikut

ip (R

M)/

Tot

al &

Fee

Co

llect

ed

7,38

1 8,

052

8,75

2

L

AM

PIR

AN

2

1 | L

ap

or

an

T

ah

un

an

2

01

2

Jen

is k

elu

lus

an

/ T

yp

e o

f A

pp

roval

20

10

201

1

20

12

Perm

it d

i ba

wa

h P

eri

nta

h K

asta

m / P

erm

it

Un

de

r C

usto

ms O

rde

r

Lara

ng

an I

mp

ort

/ Im

po

rt P

roh

ibitio

n

24

4

43

2

384

Lara

ng

an E

ksp

ort

/ E

xp

ort

Pro

hib

itio

n

64

4

68

6

775

Ob

liga

si d

i b

aw

ah

Art

icle

12

, 1

98

8

Co

nve

ntio

n/

Ob

liga

tio

n U

nd

er

Art

icle

12

, 19

88

C

on

ve

ntio

n

Ma

klu

mb

ala

s P

EN

/ P

EN

Fe

ed

ba

ck

1,8

47

1,9

09

2,2

27

PE

N d

ike

lua

rkan

/ P

EN

Issu

ed

7

02

71

7

761

Sura

t ke

ben

ara

n E

ksp

ort

Pe

rse

dia

an

Me

nga

nd

un

gi P

reku

rso

r/ L

ette

r o

f A

uth

ori

sa

tio

n fo

r P

rep

ara

tio

n C

on

tain

ing

Pre

cu

rsor

93

* M

ula

i 1 J

anuari 2

011

pers

edia

an in

i d

imasukkan

ke d

ala

m L

ara

ngan E

ksport

/ S

tart

ing 1

January

2011, th

e

pre

para

tion h

as b

een

in

clu

ded

under

Export

P

rohib

itio

n

Sura

t ke

ben

ara

n E

ksp

ort

Pe

rse

dia

an

Me

nga

nd

un

gi D

extr

om

eth

op

han

/ L

ett

er

of

Au

thorisa

tion

fo

r P

rep

ara

tio

n C

on

tain

ing

De

xtr

om

eth

op

ha

n

21

4

0

18

Page 67: program farmasi / pharmacy programme

66 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

L

AM

PIR

AN

2

1 | L

ap

or

an

T

ah

un

an

2

01

2

Jen

is k

elu

lus

an

/ T

yp

e o

f A

pp

roval

20

10

201

1

20

12

Perm

it d

i ba

wa

h P

eri

nta

h K

asta

m / P

erm

it

Un

de

r C

usto

ms O

rde

r

Lara

ng

an I

mp

ort

/ Im

po

rt P

roh

ibitio

n

24

4

43

2

384

Lara

ng

an E

ksp

ort

/ E

xp

ort

Pro

hib

itio

n

64

4

68

6

775

Ob

liga

si d

i b

aw

ah

Art

icle

12

, 1

98

8

Co

nve

ntio

n/

Ob

liga

tio

n U

nd

er

Art

icle

12

, 19

88

C

on

ve

ntio

n

Ma

klu

mb

ala

s P

EN

/ P

EN

Fe

ed

ba

ck

1,8

47

1,9

09

2,2

27

PE

N d

ike

lua

rkan

/ P

EN

Issu

ed

7

02

71

7

761

Sura

t ke

ben

ara

n E

ksp

ort

Pe

rse

dia

an

Me

nga

nd

un

gi P

reku

rso

r/ L

ette

r o

f A

uth

ori

sa

tio

n fo

r P

rep

ara

tio

n C

on

tain

ing

Pre

cu

rsor

93

* M

ula

i 1 J

anuari 2

011

pers

edia

an in

i d

imasukkan

ke d

ala

m L

ara

ngan E

ksport

/ S

tart

ing 1

January

2011, th

e

pre

para

tion h

as b

een

in

clu

ded

under

Export

P

rohib

itio

n

Sura

t ke

ben

ara

n E

ksp

ort

Pe

rse

dia

an

Me

nga

nd

un

gi D

extr

om

eth

op

han

/ L

ett

er

of

Au

thorisa

tion

fo

r P

rep

ara

tio

n C

on

tain

ing

De

xtr

om

eth

op

ha

n

21

40

18

Page 68: program farmasi / pharmacy programme

67PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

L

AM

PIR

AN

2

2 | L

ap

or

an

T

ah

un

an

2

01

2

PEM

AN

TAUA

N IK

LAN

| A

DVER

TISE

MEN

TS M

ON

ITO

RIN

G

JA

DU

AL

5:

KE

LU

LU

SA

N P

ER

MO

HO

NA

N IK

LA

N (

201

0-2

01

2)

TA

BL

E 5

: A

DV

ER

TIS

EM

EN

T A

PP

RO

VA

LS

(2

010

-201

2)

Tah

un

| Y

ear

20

10

20

11

2

012

Bil

an

ga

n P

erm

oh

on

an

Ya

ng

Dit

eri

ma

To

tal

Nu

mb

er

of

Ap

pli

cati

on

s

1, 6

02

1,6

34

2

,13

3

Ju

mla

h B

ila

ng

an

Ke

lulu

san

To

tal

Nu

mb

er

of

Ap

pro

vals

1,4

18

1,5

14

1

,67

6

Ju

mla

h B

ila

ng

an

Tid

ak

Lu

lus

To

tal

Nu

mb

er

of

No

t A

pp

rov

ed

43

2

5

17

Ju

mla

h B

ila

ng

an

Tid

ak

Pe

rlu

Ke

lulu

sa

n

To

tal

Nu

mb

er

of

No

t R

eq

uir

ed

Ap

pro

va

ls

57

2

2

18

Yu

ran

Dik

uti

p (

RM

)

Fe

es

Co

lle

cte

d (

RM

)

160

,20

0

163

,40

0

21

3,3

00

Nota

: Ju

mla

h p

erm

oho

na

n y

an

g d

ipro

se

s t

idak s

am

a d

enga

n j

um

lah

pe

rmoh

on

an

ya

ng

dite

rim

a k

era

na

terd

apa

t p

erm

oh

on

an

-pe

rmoh

on

an

ya

ng

dita

ng

gu

hka

n

da

n t

ert

utu

p s

eca

ra a

uto

ma

tik ji

ka

ma

klu

mb

ala

s d

ari p

em

oh

on

tid

ak d

ite

rim

a s

ele

pa

s te

mp

oh

pe

na

ng

gu

han

ya

ng

dib

erikan (

1 b

ula

n d

ari t

arikh

su

rat

dik

elu

ark

an).

N

ote

s:

To

tal n

o.

of

app

lica

tio

n p

rocesse

d is n

ot

the

sam

e a

s t

ota

l n

o.

of

ap

plic

atio

n r

ece

ive

d a

s t

he

re a

re f

ew

ap

plic

atio

ns w

ithh

old

or

clo

se

d a

uto

matic

ally

sin

ce

the

re is n

o r

esp

on

se f

rom

th

e a

pp

lica

nt

afte

r th

e d

ate

line

giv

en

(1

mo

nth

fro

m t

he

da

te o

f le

tte

r is

su

ed

)

Page 69: program farmasi / pharmacy programme

68 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

L

AM

PIR

AN

2

3 | L

ap

or

an

T

ah

un

an

2

01

2

PEN

CEG

AHA

N D

AN

KES

EDA

RAN

PEN

GG

UNA

| P

REVE

NTI

ON

AN

D C

ON

SUM

ER A

WA

REN

ESS

Ja

du

al

6:

Bil

an

ga

n C

era

ma

h,

Pam

era

n P

en

did

ika

n d

an

Dia

log

(2

01

0-2

01

2)

Ta

ble

6:

Nu

mb

er

of

Ta

lks

, E

xh

ibit

ion

s a

nd

Dia

log

ue

s (

20

10-2

01

2)

Akti

vit

i/ A

cti

vit

y

20

10

2

011

2

01

2

Ce

ram

ah

/ T

alk

38

1

38

6

482

Pa

mera

n/ E

xh

ibit

ion

51

2

60

9

637

Dia

log

/ D

ialo

gu

e

42

72

90

Page 70: program farmasi / pharmacy programme

69PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT 2012

LAMPIRAN

24 | L a p o r a n T a h u n a n 2 0 1 2

NPCB ‘s Key Statistics for 2012 / Statistik Utama BPFK bagi tahun 2012

Bilangan produk yang dinilai oleh PBKD Number of products reviewed by DCA

1211 produk/ products

• Produk semulajadi / Natural products = 565

• Produk Preskripsi / Prescription products = 357

• Supplemen kesihatan / Health Supplement = 161

• Produk bukan preskripsi / Non-prescription products = 83

• Veterinar / Veterinary = 45

Bilangan produk yang diluluskan untuk pendaftaran oleh PBKD Number of products approved by DCA from registration

633

Bilangan produk Ubat Baru yang didaftarakan Number of New Chemical Entity (NCE) products registered

50

Bilangan produk Bioteknologi yang didaftarkan Number of Biotechnology products registered

24

Bilangan produk yang dibatalkan Number of products cancelled

66 produk (kesemuanya adalah produk semulajadi) 66 products (all natural products)

Bilangan produk yang digantung Number of products suspended

25

• Produk Preskripsi / Prescription products = 12

• Produk semulajadi / Natural products = 13

LAMPIRAN

25 | L a p o r a n T a h u n a n 2 0 1 2

Bilangan Sijil Produk Pharmaceutical yang dikeluarkan Number of Certificate of Pharmaceutical Products (CPP) Issued

2247

Bilangan laporan kesan advers ubat yang diterima Number of Adverse Drug Reaction (ADR) reports received

10102

• 1903 (Adverse Event Following Immunisation-AEFI)

• 8199 (ADR excluding AEFI)

Bilangan sampel pengawasan yang diuji oleh makmal BPFK Number of Post Market Surveillance Sample tested by NPCB laboratory

1604

• Lulus ujian / Pass testing = 1476

• Gagal ujian / Fail testing = 128

Bilangan produk kosmetik yang dinotifikasi Number of cosmetic products notified

66913

Bilangan pembatalan notifikasi Number of notification cancellation

399

• Isu formulasi / Formulation issues = 261

• Sampel pengawasan / Surveillance sample = 74

• Isu Amalan Pengilangan Baik / Good Manufacturing Practice (GMP) Issues = 57

• Lain-lain / Others = 7

Bilangan Sijil Penjualan Bebas yang dikeluarkan Number of Certificate of Free Sale (CFS) Issued

2789

Bilangan Audit Fail Maklumat Produk Number of Product Information File (PIF) Audit

335

   

LAMPIRAN  

26 | L a p o r a n T a h u n a n 2 0 1 2

Bilangan sampel yang diuji Number of samples tested

2769 • Lulus ujian / Pass testing = 2390 • Gagal ujian / Fail testing = 379

Bilangan sampel yang didapati mengandungi bahan campurpalsu Number of samples tested positive for adulteration

130

Bilangan penilaian protocol dan data validasi Number of Evaluations of Protocol Analysis and Analytical Validation Data

1250

Bilangan pemeriksaan Amalan Pengilangan Baik Number of Good Manufacturing Practice (GMP) inspections

299

Bilangan lessen yang dikeluarkan Number of license issued

1832 • Lesen Pemborong / Wholesaler license =

1144 • Lesen Pengimport / Import license = 410 • Lesen Pengilang / Manufacturer license =

278 Bilangan pemeriksaan Amalan Klinikal Baik & Amalan Makmal Baik Number of Good Clinical Practice & Good Laboratory Practice inspections

21

Bilangan permohonan Lesen Import Percubaan Klinikal Number of application for Clinical Trial Import License (CTIL)

282

Page 71: program farmasi / pharmacy programme

70 PROGRAM FARMASI / PHARMACY PROGRAMME

LAPORAN TAHUNANANNUAL REPORT2012

   

LAMPIRAN  

26 | L a p o r a n T a h u n a n 2 0 1 2

Bilangan sampel yang diuji Number of samples tested

2769 • Lulus ujian / Pass testing = 2390 • Gagal ujian / Fail testing = 379

Bilangan sampel yang didapati mengandungi bahan campurpalsu Number of samples tested positive for adulteration

130

Bilangan penilaian protokol dan data validasi Number of Evaluations of Protocol Analysis and Analytical Validation Data

1250

Bilangan pemeriksaan Amalan Pengilangan Baik Number of Good Manufacturing Practice (GMP) inspections

299

Bilangan lesen yang dikeluarkan Number of license issued

1832 • Lesen Pemborong / Wholesaler license =

1144 • Lesen Pengimport / Import license = 410 • Lesen Pengilang / Manufacturer license =

278 Bilangan pemeriksaan Amalan Klinikal Baik & Amalan Makmal Baik Number of Good Clinical Practice & Good Laboratory Practice inspections

21

Bilangan permohonan Lesen Import Percubaan Klinikal Number of application for Clinical Trial Import License (CTIL)

282

LAMPIRAN

27 | L a p o r a n T a h u n a n 2 0 1 2

Bilangan pertanyaan yang diterima oleh Helpdesk BPFK Number of enquiry received by NPCB’s Helpdesk

5971

• Telefon / Telephone = 4189

• E-mail & Modul Pertanyaan / E-mail & Enquiry module = 832

• Pertanyaan di kaunter / Walk-in = 950

Page 72: program farmasi / pharmacy programme